Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis

Carlo Lavia¹*, Laura Dallorto¹*, Milena Maule², Manuela Ceccarelli³, Antonio Maria Fea¹*

¹ Eye Clinic, Department of Surgical Sciences, University of Turin, Turin, Italy, ² Department of Medical Sciences, University of Turin and CPO-Piemonte, AOU Città della Salute e della Scienza di Torino, Turin, Italy, ³ SCDU Epidemiologia dei Tumori-CPO Piemonte, AOU Città della Salute e della Scienza di Torino, Turin, Italy

* These authors contributed equally to this work.
* antoniomfea@gmail.com

Abstract

Background

MIGS have been developed as a surgical alternative for glaucomatous patients.

Purpose

To analyze the change in intraocular pressure (IOP) and glaucoma medications using different MIGS devices (Trabectome, iStent, Excimer Laser Trabeculotomy (ELT), iStent Supra, CyPass, XEN, Hydrus, Fugo Blade, Ab interno canaloplasty, Goniscopy-assisted translimbal trabeculotomy) as a solo procedure or in association with phacoemulsification.

Methods

Randomized control trials (RCT) and non-RCT (non randomized comparative studies, NRS, and before-after studies) were included. Studies with at least one year of follow-up in patients affected by primary open angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma were considered. Risk of Bias assessment was performed using the Cochrane Risk of Bias and the ROBINS-I tools. The main outcome was the effect of MIGS devices compared to medical therapy, cataract surgery, other glaucoma surgeries and other MIGS on both IOP and use of glaucoma medications 12 months after surgery. Outcomes measures were the mean difference in the change of IOP and glaucoma medication compared to baseline at one and two years and all ocular adverse events. The current meta-analysis is registered on PROSPERO (reference n° CRD42016037280).

Results

Over a total of 3,069 studies, nine RCT and 21 case series with a total of 2.928 eyes were included. Main concerns about risk of bias in RCTs were lack of blinding, allocation concealment and attrition bias while in non-RCTs they were represented by patients’ selection, masking of participants and co-intervention management. Limited evidence was found...
based on both RCTs and non RCTs that compared MIGS surgery with medical therapy or other MIGS. In before-after series, MIGS surgery seemed effective in lowering both IOP and glaucoma drug use. MIGS showed a good safety profile: IOP spikes were the most frequent complications and no cases of infection or BCVA loss due to glaucoma were reported.

Conclusions
Although MIGS seem efficient in the reduction of the IOP and glaucoma medication and show good safety profile, this evidence is mainly derived from non-comparative studies and further, good quality RCTs are warranted.

Introduction
Glaucoma is the second commonest cause of blindness worldwide [1]. To date, the main treatment for preventing glaucomatous damage consists in lowering intraocular pressure (IOP)[2]. The first ocular hypotensive approach is commonly eye-drop medications, whose instillation is often needed more than once per day. Poor compliance [3–4] and tolerability [5–6] can sometimes lead to treatment failure. Ab externo filtration surgery is still considered the gold standard but it is reserved to progressive disease and may lead to significant complications [7,8]. Minimally-invasive glaucoma surgeries (MIGS) have been developed as safer and less traumatic surgical interventions for patients with mild to moderate glaucoma or who are intolerant to standard medical therapy [9]. According to the commonly accepted definition, MIGS are surgical procedures with an ab-interno approach, minimal trauma with very little or no scleral dissection, minimal or no conjunctival manipulation, good safety profile and rapid recovery [10].

MIGS devices can be divided in: trabecular, suprachoroidal and subconjunctival based [11]. They can be performed in association with cataract surgery or as a solo procedure [12].

The trabecular based devices work by improving trabecular outflow through Schlemm’s canal. The suprachoroidal based devices improve the uveoscleral outflow through a connection between the anterior chamber and the suprachoroidal space while the subconjunctival devices create an alternative outflow pathway of the aqueous humor to the subconjunctival space [13,14].

There is a growing interest about MIGS procedures and several clinical studies have been published in the past years. This increase in surgical options should be supported by a clear evidence of their efficacy, to give the surgeon a detailed panorama on the potential surgical options.

However, many clinical studies have been small, nonrandomized, and often lacking appropriate control arms. Moreover, these studies often exhibit great variability in measured outcomes, definition of success/failure and follow-up periods.

The purpose of the current meta-analysis is to analyze available data on MIGS and to summarize and quantify their effect on both intraocular pressure and use of topical glaucoma medications as well as their safety profile.

Materials and methods
In this research, we adhered to the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Protocol and registration

The current meta-analysis is registered on PROSPERO (reference n˚ CRD42016037280) and is available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037280. During the peer-review process, extensive changes were required to the original protocol.

Literature search strategy

The construction of search strategies was performed by an expert epidemiologist (MC) using database specific subject headings and keywords. Electronic databases search was performed by two clinicians (LD, CL) and a third member (AF) in case of disagreement. Articles published between January 1, 2000 and December 31, 2016 were included.

Information sources included: MEDLINE Daily and MEDLINE (Ovid), MEDLINE In-Process and Other Non-Indexed Citations, CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register), EMBASE (Ovid), Latin American and Caribbean Literature on Health Sciences (LILACS), CINAHL (EBSCO), Trip Database and The National Institute for Health and Care Excellence (NICE). The search strategies for MEDLINE are included in the supplementary material (S1 Appendix). These searches were supplemented by hand searching the bibliographies of all the included studies. Grey literature was not considered in this meta-analysis due to excessive lack of essential information that usually affects this type of research.

Study selection

Study design: Randomized controlled trials (RCT) and non-RCT (non-randomized comparative studies, NRS, and before-after studies) were included. Accepted languages of publication were: English, German, French, Spanish, Portuguese and Italian.

Exclusion criteria:
1. Follow-up shorter than 12 months.
2. Glaucoma types other than primary open angle glaucoma (POAG), pseudoexfoliative (PEX) and pigmentary glaucoma (PG).
3. Number of patients lost at follow-up equal or greater than 15% (in non RCT studies)
4. Any previous glaucoma surgery except laser trabeculoplasty.
5. Studies including patients younger than 18 years.

Interventions:
In accordance with the provided definition of MIGS we included studies regarding:

• Ab interno trabeculotomy, Trabectome device (NeoMedix, Tustin, CA, USA)
• Trabecular Microbypass Stent (iStent, Glaukos, Laguna Hills, CA, USA)
• Schlemm’s Canal Scaffold (Hydrus, Ivantis, Irvine, CA, USA)
• Suprachoroidal Microstent (Cypass Transcend Medical, Menlo Park, CA, USA)
• iStent Supra (iStent, Glaukos, Laguna Hills, CA, USA)
• XEN Subconjuntival Implant gel stent (Aquesys, Aliso Viejo, CA, USA/ Allergan, Irvine, CA, USA)
• Ab interno Canaloplasty (ABIC)
• Excimer Laser Trabeculotomy (ELT, Glautec AG, Nurnberg, Germany)
• Gonioscopy-Assisted Transluminal Trabeculotomy (GATT)
• Fugo plasma blade (MediSurg Research and Management Corp., Norristown, PA, USA)

Studies about MIGS as a solo procedure or combined with cataract surgery were considered.

Screening of titles and abstracts was carried out and not pertinent articles were rejected. Full texts of residual articles were evaluated independently for eligibility. The process was made according to the PRISMA flow diagram. Duplicates were removed using EPPI reviewer (by EPPI-Center, Social Science Research Unit, the Institute of Education, the University of London, UK).

Data collection and risk of bias assessment

The main outcome of this meta-analysis was the effect of MIGS devices compared to medical therapy, cataract surgery, other glaucoma surgeries and other MIGS on the change in both IOP and use of glaucoma medications 12 months after surgery. Outcomes were analyzed separately for every MIGS, as well as for the solo and the combined procedures.

Secondary outcomes were:

• the effect of MIGS on the change in IOP and glaucoma medications between baseline and 12 and 24 months
• surgery-related adverse events.

The measure of effect was the mean change in IOP (mmHg) and the mean change in number of antiglaucoma medications, since change is expected to be less dependent of differences in baseline values.

Data were collected from each study independently by two reviewers (LD, CL). In order to obtain or confirm missing or uncertain data from investigators, corresponding Authors were contacted twice by email. In case of impossibility to obtain missing/incomplete data from corresponding Authors, data were extrapolated from figures/graphics when available. Given the potential inaccuracy of these data, outcomes were also analyzed separately excluding all inferred-results-studies, as a sensitivity analysis.

The quality assessment was evaluated with the latest version of the risk of Bias tool recommended in the Cochrane handbook for systematic review of Interventions (Chapter 8, Higgins 2011) [15] for RCT and the ROBINS-I checklist for non-RCT [16]. RCT studies were judged for the selection bias, performance bias, detection bias, attrition bias, reporting bias and other sources of bias.

Non RCT studies were judged for confounding bias, selection bias, bias in classification of interventions, bias in deviation from intended interventions, bias due to missing data, bias in measurement of outcome and bias in selection of the reported results. Results from ROBINS-I were separately reported for NRS and before-after studies, considering that the use of ROBINS-I in before-after studies is exploratory and has not been validated yet.

Studies were not excluded a priori based on quality reporting assessment.

Data synthesis and analysis

Data were analyzed from March to May 2017. Statistical analysis was performed using STATA (software version 13.1, STATA corporation, College Station, TX, USA). The random effect method was used to perform statistical analysis.

We presented mean and standard error (SE) of the IOP and number of glaucoma medication at baseline and endpoint were used to compute their mean reduction and mean and
standard deviation of IOP percentage of reduction (IOPR %, SD-IOPR%): 

\[ \text{IOPR} = \text{IOP}_{\text{baseline}} - \text{IOP}_{\text{endpoint}} \]

\[ \text{IOPR} \% = \frac{\text{IOPR}}{\text{IOP}_{\text{baseline}}} \]

\[ \text{SD} - \text{IOPR} \% = \sqrt{\left(\frac{\text{SE}_{\text{baseline}}}{\text{IOP}_{\text{baseline}}}\right)^2 + \left(\frac{\text{SE}_{\text{endpoint}}}{\text{IOP}_{\text{baseline}}}\right)^2} \cdot \sqrt{n} \]

(n: number of patients at the baseline).

When a meta-analysis was possible, summary effect measures were reported as weighted mean difference [17,18]; when the SD of the mean change was not available, the following formula was used to imputed it:

\[ \text{SD}_{\text{CHANGE}} = \sqrt{\text{SD}_{\text{baseline}}^2 + \text{SD}_{\text{final}}^2 - (2 \times \text{Corr} \times \text{SD}_{\text{baseline}} \times \text{SD}_{\text{final}})} \]

A correlation value (Corr) of 0.3 was used as it was the median value of the available SD values.

To investigate heterogeneity among studies, I^2 statistics were computed. Large statistical heterogeneity was generally found, due to the large precision of estimates in this type of matched studies and to the use of continuous outcomes [19]. We had planned to use funnel plots were generated and both Egger’s [20] and Begg’s [21] tests to assess the risk of publication bias but the limited number of studies did not allow this type of testing.

Results

Study selection

A total of 3,069 studied were screened using the described search strategy. At the end of the selection process, 30 studies were identified [22–51]. 3 out of 30 studies compared Trabectome with iStent surgery [22,23,25] while 2 out of 30 studies compared Trabectome combined and solo procedures [26,27]. Analyzed studies included 9 RCTs (Trabectome = 0, iStent = 6, CyPass = 1, Aquesys = 0, Hydrus = 1 and ELT = 1) and 21 non-RCTs (Trabectome = 7 (7 NRS), iStent = 11 (4 NRS, 7 before-after), CyPass = 1 (before-after), Hydrus = 2 (2 NRS) and ELT = 2 (1 NRS, 1 before-after). The RCTs included 850 eyes while 2,078 eyes were included in the non RCTs studies (1,598 eyes in NRS, 480 eyes in before-after studies). No studies regarding iStent Supra, ABIC, GATT and Fugo Blade met the eligibility criteria. Overall there were 20 studies about combined procedures (1521 eyes) and 15 about solo procedures (1407 eyes). Further details on included studies are given in the Prisma flow diagram (Fig 1).

Excluded studies on the basis of full-text are referenced in the supplementary material (S2 Appendix).

Study characteristics

Baseline characteristics of included studies are reported in Table 1.

Tables 2 and 3 reported IOP and number of medications at baseline and 1-year follow-up in different type of studies, together with their percent reduction.

In two studies [30,33] missing data were taken from previous papers by the same authors [52,53], being the former the long-term follow-up studies.
Baseline characteristics of included patients who were given indication for MIGS therapy were highly variable in terms of glaucoma severity, IOP values (e.g medicated and unmedicated) and number of glaucoma medications. The majority of studies reported visual field and clinical parameters to describe the baseline glaucoma severity of patients. In all the studies but three mild to moderate glaucoma were included, while in three papers advanced glaucoma (Mean Deviation ≤ -12 dB) and need for filtrating surgery were baseline findings [44].
Table 1. Baseline characteristics of included studies.

| Device          | Author, Year (Study Design) | Comparator                                                      | Eyes (n) | Age (Years) Mean ± SD | Sex M/F (%) | POAG (%) | PEX (%) | PIGM (%) | Follow-up (months) |
|-----------------|-----------------------------|----------------------------------------------------------------|----------|------------------------|-------------|-----------|---------|----------|-------------------|
| TRABECTOME      |                             | ISTENT COMBINED                                                | 27       | 73.8 ± 7.8             | 48/52       | 70        | 30      | 0        | 12                |
|                 |                             | ISTENT COMBINED                                                | 52       | 76.1 ± 12.1            | 44/56       | 96        | 2       | 2        | 12                |
|                 |                             | TRABECULAR ASPIRATION COMBINED                                  | 27       | 73.4 ± 10.8            | 56/44       | 0         | 100     | 0        | 12                |
|                 |                             | ISTENT COMBINED                                                | 36       | 72.4 ± 9.6             | 53/47       | 56        | 44      | 0        | 12                |
|                 |                             | TRABECTOME SOLO                                                | 130      | NR                     | NR          | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME SOLO                                                | 54       | NR                     | NR          | 0         | 100     | 0        | 12                |
|                 |                             | TRABECTOME SOLO                                                | 263      | 74 ± 9                 | 40/59       | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME SOLO                                                | 45       | 78 ± 7                 | 24/73       | 0         | 100     | 0        | 12                |
| SOLO            |                             | TRABECTOME COMBINED                                            | 72       | NR                     | NR          | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME COMBINED                                            | 119      | NR                     | NR          | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME COMBINED                                            | 10       | 63.9 ± 3.2             | 30/70       | 100       | 0       | 0        | 12                |
|                 |                             | PHACOEMULSIFICATION ALONE                                      | 10       | 63.9 ± 3.2             | 30/70       | 100       | 0       | 0        | 12                |
|                 |                             | PHACOEMULSIFICATION ALONE                                      | 119      | 73.9 ± 9.6             | 100         | 0         | 0       | 12                |
|                 |                             | PHACOEMULSIFICATION ALONE                                      | 27       | 75.2 ± 8.0             | 0           | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME COMBINED                                            | 450      | 68 ± 15                | 40/57       | 100       | 0       | 0        | 12                |
|                 |                             | TRABECTOME COMBINED                                            | 67       | 78 ± 7                 | 24/73       | 0         | 100     | 0        | 12                |
| ISTENT          |                             | COMBINED                                                       | 19       | 74.6 ± 8.4             | 47/53       | 79        | 10.5    | 10.5     | 60                |
|                 |                             | 1 STENT                                                        | 117      | 74 ± 8                 | 39/61       | 91        | 6       | 3        | 24                |
|                 |                             | 2 STENT                                                        | 10       | 63.9 ± 3.2             | 30/70       | 100       | 0       | 0        | 12                |
|                 |                             | 2 STENT                                                        | 119      | 73.9 ± 9.6             | 100         | 0         | 0       | 12                |
|                 |                             | 2 STENT                                                        | 28       | 78.8 ± 7               | 27/73       | 75        | 25      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 17       | 75.2 ± 7.2             | 35/65       | 88.2–11.8 | 0       | 0        | 12                |
|                 |                             | 2 STENT                                                        | 27       | 73.8 ± 7.8             | 48/52       | 70        | 30      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 49       | 77.5 ± 11.9            | 41/59       | 78        | 22      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 34       | 75.0 ± 10.3            | 44/56       | 56        | 44      | 0        | 12                |
| SOLO            |                             | 1 STENT                                                        | 20       | 75.1 ± 8.6             | 45/55       | 40–40 OHT | 20       | 0        | 60                |
|                 |                             | 2 STENT                                                        | 28       | 78.8 ± 7               | 27/73       | 75        | 25      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 17       | 75.2 ± 7.2             | 35/65       | 88.2–11.8 | 0       | 0        | 12                |
|                 |                             | 2 STENT                                                        | 27       | 73.8 ± 7.8             | 48/52       | 70        | 30      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 49       | 77.5 ± 11.9            | 41/59       | 78        | 22      | 0        | 12                |
|                 |                             | 2 STENT                                                        | 34       | 75.0 ± 10.3            | 44/56       | 56        | 44      | 0        | 12                |
| 1 STENT         |                             | 1 STENT                                                        | 38       | 68.1 ± 9.1             | 71/29       | 100       | 0       | 0        | 18                |
|                 |                             | 2 STENT                                                        | 39       | 62.8 ± 12.6            | 54/46       | NR       | NR      | NR       | 18                |
|                 |                             | 2 MEDICATIONS                                                  | 39       | 66.7 ± 10.0            | 56/44       | NR       | NR      | NR       | 36                |
|                 |                             | 2 MEDICATIONS                                                  | 94       | 64.5 ± 10.3            | 39/61       | NR       | NR      | NR       | 12                |

(Continued)
**Table 1.** (Continued)

| Device | Author, Year | Study Design | Comparator | Eyes (n) | Age (Years) Mean ± SD | Sex MF (%) | POAG (%) | PEX (%) | PIGM (%) | Follow-up (months) |
|--------|--------------|--------------|------------|---------|-----------------------|------------|----------|---------|---------|-------------------|
|        | KATZ, 2015*56 | RCT          | 1 AND 2 ISTENT SOLO | 41      | 67.8 ± 9.3            | 46/54      | 97.6     | 2.4     | 0       | 18                |
|        | LINDSTROM, 2016*57 (INJECT) | BEF-AFT STUDY | N/A       | 57      | 65.3 ± 9.0            | 53/47      | 100      | 0       | 0       | 18                |
|        | VOLD, 2016*61 | RCT          | MEDICATION | 54      | 64.5 ± 11.1           | 46/54      | 100      | 0       | 0       | 36                |
|        | VOSKANYAN, 2014*12 (INJECT) | BEF-AFT STUDY | N/A       | 99      | 66.4 ± 10.9           | 43/57      | 97       | 3       | 0       | 12                |
|        | 3 STENT      | KATZ, 2015*56 | RCT | 1 AND 2 ISTENT SOLO | 40      | 60.9 ± 8.1            | 48/52      | 100      | 0       | 0       | 18                |
|        | CYPASS       | COMBINED     |            |         |                       |            |          |         |         |                   |
|        | VOLD, 2016*63 | RCT          | PHACOEMULSIFICATION ALONE | 374    | 70.0 ± 8.0            | 47/53      | 100      | 0       | 0       | 24                |
|        | XEN          | COMBINED     |            |         |                       |            |          |         |         |                   |
|        | PEREZ-TORREGROSA, 2016*65 | BEF-AFT STUDY | N/A       | 30      | 76 ± 5.9              | 28/72      | 100      | 0       | 0       | 12                |
|        | HYDRUS       | COMBINED     |            |         |                       |            |          |         |         |                   |
|        | PFEIFFER, 2015*66 | RCT          | PHACOEMULSIFICATION ALONE | 50     | 72.8 ± 6.6            | 40/60      | 90       | 10      | 0       | 24                |
|        | SOLO         |            |            |         |                       |            |          |         |         |                   |
|        | GANDOLFI, 2016*67 | NRS          | CANALOPLASTY AB EXTERNO | 21    | NR                    | 71/29      | 57.1     | 33.3    | 9.5     | 24                |
|        | FEA, 2016*68 | NRS          | SLT        | 31      | 70.8 ± 11.8           | 58/42      | 100      | 0       | 0       | 12                |
|        | ELT          | COMBINED     |            |         |                       |            |          |         |         |                   |
|        | TÖTEBERG-HARMS, 2013*69 | BEF-AFT STUDY | N/A       | 64      | 76.5 ± 9.4            | 34/66      | 33–3     | NTG—6   | OHT    | 58                |
|        | SOLO         |            |            |         |                       |            |          |         |         |                   |
|        | BABIGHIAN, 2006*50 | NRS          | MEDICAL THERAPY (FELLOW EYE) | 21    | 58 ± 8.9              | 43/57      | 100      | 0       | 0       | 24                |
|        | BABIGHIAN, 2010*51 | RCT          | SLT        | 15      | 65.2 ± 4.6            | 40/60      | 100      | 0       | 0       | 24                |

Number rounded to the first decimal digit. If data discordance between text and tables, data from the text was chosen. SD = standard deviation. NRS = non-randomized study of intervention. RCT = randomized controlled trial. Bef-aft study = before-after study. POAG = primary open angle glaucoma. Pex = pseudoexfoliative glaucoma. Pigm = pigmentary glaucoma. NTG = normal tension glaucoma. OHT = ocular hypertension. NR = not reported. N/A = not applicable

*a* = demographic data from 27 patients, IOP and medication data from 25 eyes of 25 patients (excluded from the study patients with secondary glaucoma surgery).

*b* = demographic and baseline data obtained from Samuelson 2011*52*.

*c* = reported by corresponding author.

*d* = OAG subtypes data from intention-to-treat(ITT) population (58 patients), demographic and baseline data from per-protocol(PP) population (48 patients).

*e* = 3 patients received only 1 iStent. Demographic data from Arriola-Villalobos 2013*53*.

*f* = 3-iStent group data excluded because of 8% mixed mechanism.

https://doi.org/10.1371/journal.pone.0183142.t001
Table 2. IOP and antiglaucoma medication values at baseline and one year in RCT and NRS.

| Study Design | Group 1 | Group 2 |
|--------------|---------|---------|
|              | Eyes (n) | IOP Bas (mmHg) Mean ± SD | IOP 1 year (mmHg) Mean ± SD | Med Bas (n) Mean ± SD | Med 1 year (n) Mean ± SD | Med Reduction (n) |
| NRS TRABECTOME | 23.2 ± 2.3 | 15.6 ± 3.6 | 30.6 ± 23.2 | 2.1 ± 1.1 | 1.4 ± 1.3 | 0.64 |
| NRS TRABECTOME | 20.6 ± 6.8 | 17.3 ± 6.0 | 16.0 ± 46.7 | 2.0 ± 1.1 | 2.2 ± 1.4 | 0.75 |
| NRS TRABECTOME | 27.3 ± 2.3 | 14.1 ± 2.3 | 39.7 ± 26.9 | 2.3 ± 1.0 | 2.1 ± 0.9 | 0.29 |
| NRS TRABECTOME | 20.5 ± 5.1 | 15.8 ± 3.8 | 24.3 ± 20.8 | 2.3 ± 1.3 | 1.8 ± 1.3 | 0.49 |
| NRS TRABECTOME | 23.3 ± 2.3 | 14.1 ± 2.3 | 39.7 ± 26.9 | 2.3 ± 1.0 | 2.1 ± 0.9 | 0.29 |
| NRS TRABECTOME | 27.3 ± 2.3 | 14.1 ± 2.3 | 39.7 ± 26.9 | 2.3 ± 1.0 | 2.1 ± 0.9 | 0.29 |
| NRS TRABECTOME | 21.7 ± 2.3 | 14.2 ± 2.3 | 34.6 ± 21.4 | 2.5 ± 1.0 | 1.6 ± 1.3 | 0.96 |
| NRS TRABECTOME | 22.0 ± 9.8 | 12.3 ± 2.7 | 44.0 ± 45.2 | 2.4 ± 1.0 | 1.8 ± 0.8 | 0.56 |
| RCT 1 ISTENT COMBINED | 18.6 ± 3.4 | 17.2 ± 2.8 | 8.6 ± 23.7 | 1.6 ± 0.8 | 0.2 ± 0.6 | 1.40 |
| RCT 1 ISTENT COMBINED | 17.8 ± 2.7 | 14.7 ± 1.3 | 17.4 ± 16.8 | 1.9 ± 0.9 | 0.4 ± 0.7 | 1.50 |
| RCT 1 ISTENT COMBINED | 24.2 ± 1.8 | 17.6 ± 2.8 | 7.3 ± 13.8 | 1.1 ± 0.5 | 0.0 ± 0.0 | 1.10 |
| RCT 1 ISTENT COMBINED | 18.9 ± 1.3 | 14.4 ± 1.2 | 27.3 ± 9.0 | 1.7 ± 0.6 | 0.1 ± 0.3 | 1.60 |
| RCT 2 ISTENT (INJECT) | 21.1 ± 1.7 | 13.2 ± 3.2 | 38.4 ± 13.6 | 1.0 ± 0.9 | 0.04 ± 0.2 | 0.96 |
| RCT 2 ISTENT (INJECT) | 25.5 ± 2.5 | 13.7 ± 1.9 | 46.3 ± 12.4 | 0 | 0.09 ± 0.4 | 0.47 |
| RCT 2 ISTENT (INJECT) | 24.4 ± 2.6 | 16.0 ± 2.5 | 32.4 ± 21.1 | 1.4 ± 0.9 | 0.2 ± 0.6 | 1.20 |
| RCT 2 HYDRUS COMBINED | 18.3 ± 3.3 | 16.1 ± 3.0 | 14.8 ± 20.7 | 2.1 ± 0.9 | 0.2 ± 0.3 | 1.50 |
| RCT 2 HYDRUS COMBINED | 18.3 ± 3.3 | 16.1 ± 3.0 | 14.8 ± 20.7 | 2.1 ± 0.9 | 0.2 ± 0.3 | 1.50 |
| RCT 2 HYDRUS COMBINED | 24.8 ± 2.0 | 16.2 ± 2.5 | 34.7 ± 11.7 | 2.2 ± 0.6 | NR | 0.21 |
| RCT 2 HYDRUS COMBINED | 25.0 ± 1.9 | 16.0 ± 2.2 | 36.0 ± 11.6 | 2.3 ± 0.6 | NR | 0.23 |
| RCT 2 HYDRUS SLT | 21.6 ± 1.6 | 21.6 ± 2.0 | 21.0 ± 2.0 | 2.8 ± 1.9 | NR | NR |
| RCT 2 HYDRUS SLT | 23.9 ± 0.9 | 19.0 ± 1.8 | 20.5 ± 8.4 | 2.2 ± 0.7 | NR | NR |

Number rounded to the first decimal digit, (second decimal for medication reduction). If data discordance between text and tables, the text for medication reduction. SD = standard deviation. NRS = non randomized study of intervention. RCT = randomized controlled trial. POAG = primary open angle glaucoma. Pex = pseudoexfoliative glaucoma. IOP = intraocular pressure. NR = not reported. N/A = not applicable.

d = demographic data from 27 patients, IOP and medication data from 25 eyes of 25 patients (excluded patients with secondary glaucoma surgery).

b = LOCF (last observation carried forward).

c = data inferred from graphics/figures.

d = demographic and baseline data obtained from Samuelson 2011 [52]; outcomes obtained from Craven 2012 [50] (consistent cohort of 98 eyes).

e = wash-out iop.

f = medication use protocol.

g = reported by corresponding author.

h = naïve glaucoma patients.
i = 1-year IOP from PP population (332 eyes), all other data from ITT population (374 eyes).

https://doi.org/10.1371/journal.pone.0183142.t002
Medicated IOP had to be between 18 and 30 mmHg in some studies [e.g. 36, 37, 38, 40], even though different thresholds were chosen by other authors (i.e. 14–30 mmHg [33], 17–31 mmHg [35], 21–35 mmHg [44], > 18 mmHg [25]). Some inclusion criteria considered as a cutoff value the target IOP [e.g. 22,34].

Washed-out IOP values were even variable across studies, being for example 22–32 [33] or 22–38 mmHg [36, 37,38,39,40], but not all studies contemplate wash-out, mainly due to ethical implications.

Only one study [41] included naïve patients, three studies [38,39,40] in the iStent as a solo procedure group included patients on one hypotensive medication and POAG subjects on 2 topical therapy were considered eligible in the study by Ahmed [37].

Main outcomes at follow-up visit over one year are reported in Table 4.

### Risk of bias

**RCT.** Risk of bias assessment for individual RCTs are reported in S1 Table, S1 and S2 Figs. In RCT studies greater risks were found in detection and in the attrition bias. Three
Table 4. Pre- and post-operative intraocular pressure and glaucoma medications at last follow-up visit of included studies.

| Device   | Author, Year          | Eyes (N) | Postoperative Follow-up (months) | IOP Baseline (mmHg) Mean ± SD | IOP Postoperative (mmHg) mean ± SD | IOP reduction (%) mean ± SD | Medication baseline (N) Mean ± SD | Medication postoperative (N) Mean ± SD | Medication reduction (N) |
|----------|-----------------------|----------|----------------------------------|-------------------------------|-----------------------------------|-------------------------------|-----------------------------------|---------------------------------------|------------------------|
| ISTENT   |                       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
| COMBINED |                       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
| 1 STENT  | ARRIOLA-VILLALOBOS,   | 19       | 24                               | 19.4 ± 1.9                    | 16.1 ± 3.0                       | 17.0 ± 18.4                   | 1.3 ± 0.5                         | 0.3 ± 0.5                             | 1.00                   |
|          | 201229                |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | ARRIOLA-VILLALOBOS,   | 19       | 36                               | 19.4 ± 1.9                    | 15.9 ± 3.6                       | 17.9 ± 20.8                   | 1.3 ± 0.5                         | 0.6 ± 0.6                             | 0.76                   |
|          | 201229                |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | ARRIOLA-VILLALOBOS,   | 16       | 48                               | 19.4 ± 1.9                    | 16.5 ± 3.6                       | 15.2 ± 22.4                   | 1.3 ± 0.5                         | 0.5 ± 0.6                             | 0.82                   |
|          | 201229                |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | CRAVEN, 201220        | 117      | 24                               | 18.6 ± 3.4                    | 17.1 ± 2.9                       | 8.1 ± 24.0                    | 1.6 ± 0.8                         | 0.3 ± 0.6                             | 1.30                   |
|          | FEA, 201521           | 10       | 48                               | 17.8 ± 2.7                    | 15.9 ± 2.3                       | 10.7 ± 19.9                   | 1.9 ± 0.9                         | 0.5 ± 0.8                             | 1.40                   |
| 2 STENT  | ARRIOLA-VILLALOBOS,   | 19       | 24                               | 20.0 ± 3.7                    | 17.0 ± 2.3                       | 14.8 ± 22.0                   | 1.3 ± 0.7                         | 0.5 ± 0.6                             | 0.83                   |
|          | 2016 (INJECT)33       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | ARRIOLA-VILLALOBOS,   | 15       | 36                               | 20.0 ± 3.7                    | 17.1 ± 2.2                       | 14.4 ± 22.5                   | 1.3 ± 0.7                         | 0.7 ± 0.7                             | 0.57                   |
|          | 2016 (INJECT)33       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | ARRIOLA-VILLALOBOS,   | 12       | 48                               | 20.0 ± 3.7                    | 17.5 ± 3.5                       | 12.5 ± 29.2                   | 1.3 ± 0.7                         | 0.7 ± 0.8                             | 0.57                   |
|          | 2016 (INJECT)33       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | ARRIOLA-VILLALOBOS,   | 11       | 60                               | 20.0 ± 3.7                    | 16.2 ± 2.3                       | 18.9 ± 24.2                   | 1.3 ± 0.7                         | 1.1 ± 0.8                             | 0.21                   |
|          | 2016 (INJECT)33       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
| SOLO     |                       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
| 1 ISTENT | KATZ, 201526          | 36       | 18                               | 19.8 ± 1.3                    | 15.6 ± 1.5                       | 21.2 ± 10.2                   | 1.7 ± 0.6                         | 0.2 ± 0.4                             | 1.52                   |
| 2 STENT  | AHMED, 201437         | 39       | 18                               | 22.2 ± 2                      | 11.8 ± 2.1                       | 46.9 ± 13.1                   | 2 ± 04                           | 1 ± 04                               | 1.00                   |
|          | DONNENFELD, 201538    | 39       | 24                               | 20.6 ± 2                      | 13.5 ± 2.1                       | 34.5 ± 14.4                   | 1 ± 03                           | NR                                   | N/A                    |
|          | DONNENFELD, 201538    | 30       | 36                               | 20.6 ± 2                      | 15.2 ± 2.1                      | 26.2 ± 15.5                   | 1 ± 03                           | NR                                   | N/A                    |
|          | KATZ, 201526          | 41       | 18                               | 20.1 ± 1.6                    | 13.8 ± 1.3                       | 31.3 ± 10.3                   | 1.8 ± 0.5                        | 0.1 ± 0.4                             | 1.64                   |
|          | LINDSTROM, 2016       | 57       | 18                               | 19.5 ± 1.5                    | 14.4 ± 2.1                       | 26.2 ± 13.2                   | 1 ± 03                           | 0                                    | 1.0                    |
|          | (INJECT)60            |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | VOLD, 201641          | 54       | 24                               | 25.5 ± 2.5                    | 13.8 ± 1.4                      | 45.9 ± 11.3                   | 09                                | 0.13 ± 0.44                            | N/A                    |
|          | VOLD, 201641          | 34       | 36                               | 25.5 ± 2.5                    | 14.6 ± 2.4                      | 42.8 ± 15.4                   | 09                                | 0.21 ± 0.54                            | N/A                    |
| 3 ISTENT | KATZ, 201526          | 38       | 18                               | 20.4 ± 1.8                    | 12.1 ± 1.2                       | 40.7 ± 10.7                   | 1.5 ± 0.7                        | 0.1 ± 0.3                             | 1.43                   |
|          | CYPASS COMBO          |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | VOLD, 201643          | 374      | 24                               | 24.4 ± 2.8                   | 17.0 ± 3.4                      | 30.3 ± 18.7                   | 1.4 ± 0.9                        | 0.2 ± 0.6                             | 1.20                   |
|          | HYDRUS COMBINED       |          |                                  |                               |                                   |                               |                                   |                                       |                        |
|          | PFEIFFER, 201546      | 50       | 24                               | 18.9 ± 3.3                    | 16.5 ± 2.9                      | 12.7 ± 23.7                   | 2.0 ± 1.0                        | 0.5 ± 1.0                             | 1.50                   |

(Continued)
Table 4. (Continued)

| Device | Author, Year | Eyes (N) | Postoperative Follow-up (months) | IOP Baseline (mmHg) Mean ± SD | IOP Postoperative (mmHg) Mean ± SD | IOP reduction (%) Mean ± SD | Medication baseline (N) Mean ± SD | Medication postoperative (N) Mean ± SD | Medication reduction (N) |
|--------|--------------|---------|---------------------------------|-------------------------------|-----------------------------------|-----------------------------|--------------------------------------|----------------------------------------|------------------------|
| SOLO   | GANDOLFI, 2016<sup>47</sup> | 21      | 24                              | 24.0 ± 6.0                    | 15.0 ± 3.0                        | 37.5 ± 28.0                 | 3.1 ± 0.6                            | 0.9 ± 0.9                          | 2.20                   |
|        | ELT SOLO     |         |                                 |                               |                                   |                             |                                      |                                       |                         |
|        | BABIGHIAN, 2006<sup>50</sup> | 21      | 24                              | 24.8 ± 2.0                    | 16.9 ± 2.1                        | 31.9 ± 11.7                 | 2.2 ± 0.6                            | 0.7 ± 0.8                          | 1.53                   |
|        | BABIGHIAN, 2010<sup>51</sup> | 15      | 24                              | 25.0 ± 1.9                    | 17.6 ± 2.2                        | 29.6 ± 11.6                 | 2.3 ± 0.6                            | 0.7 ± 0.8                          | 1.54                   |

Data at follow-up over 1 year. SD = standard deviation. IOP = intraocular pressure. NR = not reported.

<sup>a</sup> = data inferred from graphics/figures.
<sup>b</sup> = demographic and baseline data obtained from Samuelson 2011<sup>52</sup>. Outcomes obtained from Craven 2012<sup>30</sup> (consistent cohort of 98 eyes).
<sup>c</sup> = reported by corresponding author.
<sup>d</sup> = medication use per protocol.
<sup>e</sup> = calculated on 92.3% patients without medications.
<sup>f</sup> = calculated on 93.3% patients without medications.
<sup>g</sup> = naïve glaucoma patients.
<sup>h</sup> = 2-year IOP on PP population (332 eyes), all other data on ITT population (374 eyes).
<sup>i</sup> = wash-out IOP
studies were considered at high risk of attrition bias [31] and detection bias [36,41]. Unclear risk of allocation concealment was observed in almost all studies, mainly due to incomplete description. No masking of patients, surgeons and outcome assessors seems to be the main concern among the analyzed studies, representing the most serious bias and potentially confounding the outcomes.

Funding by device industry or authors affiliations are often declared (7 out of 9 studies), details are reported in S4 Table.

**NRS.** Risk of bias assessment for NRS are reported in S2 Table and S3 Fig.

A serious risk of confounding was observed in all studies except one that applied a propensity score based on relevant baseline variables [48]. All other NRS were at serious risk of confounding bias due to a lack of baseline IOP and medication adjustment between groups. Some studies recruited consecutive patients and were judged at low risk of bias in selection of participants; other authors excluded patients who did not complete the follow-up: these papers were therefore judged at serious risk [22,23,28,47]. As MIGS and cataract surgery are well-defined once only interventions, misclassification of interventions was unlikely. Glaucoma therapy was the main cointervention, potentially causing serious performance bias. Probably due to the clinical-setting of most NRS, glaucoma medications were often reintroduced or discontinued in the follow-up at clinicians’ discretion (judged as serious risk). If glaucoma therapy was prescribed basing on target IOP, studies were considered at moderate risk [24,28,48]. In our review, studies presenting with more than 15% of patients lost at one-year follow-up were excluded to avoid as much as possible a bias due to missing data. Thus, all included studies were judged at low risk. Due to a lack in masking strategy, outcome assessment was judged at moderate risk of bias in all studies. The method of outcome assessment was thought to be comparable across intervention groups and the outcome measure was considered minimally influenced by the knowledge of intervention. Selective reporting of subgroup of participants (e.g. patients receiving secondary surgery) was observed in one study, evaluated as a serious reporting bias [22].

**Before-after studies.** We adapted the ROBINS-I for evaluating the risk of bias in before-after studies, results are reported in S3 Table and S4 Fig.

All studies, even the MIGS arms RCT and NRS were considered as before-after studies. For before-after studies confounding domain was not applicable as subjects were not assigned to different groups. Seven out of 30 studies [24,25,30,33,48,50,51] recruited consecutive patients, thus they were at low risk of bias in selection of participants; nine papers [22,23,26,27,28,34,38,42,47] were judged at serious risk of selection bias because the exclusion of some eligible participants was related to the outcome (e.g. exclusion of patients who did not complete the follow-up or received secondary surgery). In some studies lack of information about selection of participants could not permit risk assessment. Misclassification of assignment of intervention did not occur in before-after study as for NRS: MIGS and cataract surgery are well-defined once-only interventions.

Glaucoma therapy was the main cointervention, potentially causing serious performance biases. Only studies which reported washed-out IOP both pre- and post-operatively were judged to be at low risk [31,36,37,43,46]; other studies were considered at moderate risk if one between pre and post-operative IOP measure was washed-out. Only one study reported masking strategy [43]. Risk of bias due to missing data, measurement of outcome and selection of the reported results were similar to those of NRS.

Funding and authors affiliations for all studies are reported in S4 Table.

**Outcomes in comparative studies**

Outcomes are reported in Figs 2 and 3.
**MIGS devices versus cataract surgery.** Five papers (all RCT) compared MIGS and cataract surgery with cataract surgery alone on a total of 871 patients. CYPASS: one RCT [43] compared combined Cypass surgery with cataract surgery alone on 505 patients. Unmedicated

![Forest plot for comparison in IOP change between study arms at 12-months (divided by device and procedure). Values expressed in Weighed Mean Difference (WMD).](https://doi.org/10.1371/journal.pone.0183142.g002)
IOP data were reported and showed at 1 year a mean change of 7.9 ± 4.1 mmHg and 6.2 ± 3.8 mmHg in the MIGS and control groups respectively. WMD was -1.7 (95% CI -2.47, -0.93) in favor of Cypass surgery (Fig 2). The change in the number of glaucoma medication was

![Forest plot](https://doi.org/10.1371/journal.pone.0183142.g003)

### Table

| STUDY                  | design | N, mean (SD); group 1 | N, mean (SD); group 2 | WMD (95% CI) |
|------------------------|--------|-----------------------|-----------------------|--------------|
| ISTENT 1 COMB vs PHACO ALONE |        |                       |                       |              |
| Craven 2012 RCT        |        | -0.30 (-0.52, -0.08) | 98, -1.4 (.8)         | 101, -1.1 (.8) |
| Fea 2015 RCT           |        | -0.70 (-1.35, -0.05) | 10, -1.5 (.8)         | 21, -8 (1)   |
| ISTENT 2 COMB vs PHACO ALONE |        |                       |                       |              |
| Fernández-Barrientos 2016 RCT |   | -0.60 (-1.10, -0.10) | 17, -1.1 (.5)         | 16, -5 (.889) |
| CYPASS COMB vs PHACO ALONE |        |                       |                       |              |
| Void 2016 RCT          |        | -0.60 (-0.78, -0.42) | 74, -1.2 (.794)       | 131, -6 (.954) |
| HYDRUS COMB vs PHACO ALONE |        |                       |                       |              |
| Pfeiffer 2015 RCT      |        | -0.30 (-0.72, 0.12)  | 48, -1.5 (1.07)       | 49, -1.2 (1.05) |
| TRABECTOME COMB vs OTHER SURGERY | |                       |                       |              |
| Klamann 2013 NRS       |        | -0.37 (-0.96, 0.22)  | 27, -2.9 (.995)       | 28, 0.08 (1.22) |
| TRABECTOME SOLO vs OTHER SURGERY | |                       |                       |              |
| Pahlitzs 2016 POAG NRS |        | 0.85 (0.54, 1.16)    | 119, -2.5 (.895)      | 68, -1.1 (1.1) |
| Pahlitzs 2016 PEX NRS  |        | 0.11 (-0.53, 0.75)   | 27, -0.56 (.936)      | 22, -0.67 (1.28) |
| HYDRUS SOLO vs OTHER SURGERY |       |                       |                       |              |
| Fea 2016 NRS           |        | -0.91 (-1.45, -0.37) | 0, -1.39 (.97)        | 25, -0.48 (1.05) |
| ISTENT 1 SOLO vs ISTENT 2 SOLO |       |                       |                       |              |
| Katz 2015 RCT          |        | 0.04 (-0.19, 0.27)   | 37, -1.6 (.528)       | 41, -1.64 (.485) |
| TRABECTOME COMB vs ISTENT 2 COMB | |                       |                       |              |
| Gonnermann 2016 NRS    |        | 0.12 (-0.51, 0.75)   | 25, -0.64 (1.21)      | 25, -0.76 (1.06) |
| Khan 2015 NRS          |        | 0.89 (0.42, 1.36)    | 52, -0.75 (1.24)      | 49, -1.64 (1.14) |
| Kurji 2016 NRS         |        | -0.23 (-0.72, 0.26)  | 33, -0.49 (1.25)      | 31, -0.26 (7) |
1.2 ± 0.79 and 0.6 ± 0.95 in the MIGS and control group respectively. WMD was -0.6 (95% CI -0.78, -0.42) in favor of Cypass surgery (Fig 3). The IOP lowering effect of the Cypass remained stable over 2 years, as well as the glaucoma medication reduction (S5 and S6 Figs). Risk of bias analysis showed unclear risk in four domains and low risk in two domains (S1 Table).

HYDRUS: one RCT [46] compared combined Hydrus surgery with cataract surgery alone on 100 patients. Medicated IOP data were reported and showed at 1 year a mean change of 2.8 ± 3.7 mmHg and 2.6 ± 4 mmHg in the MIGS and control groups respectively. WMD was -0.2 (95% CI -1.73, 1.33) in favor of Hydrus surgery (Fig 2). Unmedicated IOP data were reported and showed at 1 year a mean change of 9.7 ± 4.5 mmHg and 9.2 ± 4.7 mmHg in the MIGS and control groups respectively. WMD was -0.5 (95% CI -2.39, 1.39) in favor of Hydrus surgery. The change in the number of glaucoma medication was 1.5 ± 1.07 and 1.2 ± 1.05 in the MIGS and control group respectively (Fig 3). WMD was -0.2 (95% CI -0.72, 0.12) in favor of Hydrus surgery. The IOP lowering effect of the Hydrus remained stable over 2 years, as well as the glaucoma medication reduction (S5 and S6 Figs). These results suggest little difference in IOP change between Hydrus surgery and cataract surgery. The study showed low risk of bias in five domains (S1 Table).

ISTENT: three RCT [30,31,35] compared combined iStent surgery with cataract surgery alone on 266 patients.

In the RCT by Craven [30], medicated IOP data were reported and showed at 1 year a mean change of 1.6 ± 3 mmHg and 0.9 ± 3.3 mmHg in the MIGS and control groups respectively. WMD was -0.7 (95% CI -1.58, 0.18) in favor of iStent surgery (Fig 2). The change in the number of glaucoma medication was 1.4 ± 0.8 and 1.1 ± 0.8 in the MIGS and control group respectively. WMD was -0.3 (95% CI -0.52, -0.08) in favor of iStent surgery (Fig 3). The IOP lowering effect of the iStent remained stable over 2 years, as well as the glaucoma medication reduction (S5 and S6 Figs). Risk of bias analysis showed unclear risk in four domains and low risk in two domains (S1 Table).

In the RCT by Fea [31], medicated IOP data were reported and showed at 1 year a mean change of 3.1 ± 2.6 mmHg and 1.1 ± 2.9 mmHg in the MIGS and control groups respectively. WMD was -2.0 (95% CI -4.04, 0.04) in favor of iStent surgery. Unmedicated IOP data were reported and showed at 1 year a mean change of -1.7 ± 2.8 mmHg and 1.7 ± 3.6 mmHg in the MIGS and control groups respectively. WMD was -3.4 (95% CI -5.74, -1.06) in favor of iStent surgery (Fig 2). The change in the number of glaucoma medication was 1.5 ± 0.8 and 0.8 ± 1 in the MIGS and control group respectively. WMD was -0.7 (95% CI -1.35, -0.05) in favor of iStent surgery (Fig 3). This study was at high risk of attrition bias and low or unclear risk of other biases (S1 Table).

In the RCT by Fernández-Barrientos [35], IOP data were reported as unmedicated and medicated values at baseline and 1 year after double iStent surgery respectively. The mean change in IOP was 6.6 ± 3 mmHg and 3.8 ± 2.7 mmHg in the MIGS and control groups respectively. WMD was -2.8 (95% CI -4.75, -0.85) in favor of iStent surgery (Fig 2). Risk of bias analysis showed unclear risk in four domains and low risk in two domains (S1 Table).

Meta-analysis was performed considering the studies by Craven [30] and Fea [31], with moderate heterogeneity (I² = 24.3%). WMD was -1.01 (95% CI -2.1, 0.08); p = 0.07 suggesting a small advantage of iStent compared to cataract surgery, but this estimate was imprecise and the 95%CI included no difference.

**MIGS devices versus medical therapy.** Three studies (2 RCTs and 1 NRS, 335 patients overall) compared MIGS (ELT and iStent as solo procedures) with standard medical therapy. ELT: in the NRS by Babighian [50], ELT was compared to medical therapy that was carried-on in fellow eyes, representing the control group. This study with a small sample size (21 patients) showed a large statistically significant IOP difference, WMD = -8.0 mmHg (95% CI
IOP change was -8.6 ± 0.9 mmHg and -0.6 ± 2.2 mmHg in the ELT and medication group, respectively (Fig 2). The study reported outcomes on the number of glaucoma medications at 2 years only, with a WMD of -1.53 (95% CI -1.96, -1.10) in the ELT group compared to baseline values (S6 Fig). IOP changes at 2 years were similar to those at 12 months (S5 Fig). This study was at high risk of bias in two domains of the tools (bias due to confounding, bias due to deviation from intended intervention), S2 Table.

ISTENT: in the RCT by Fea [39] (94 eyes in the iStent group and 98 eyes in the medication group) the medicated IOP change was 8.1 ± 2.6 mmHg in the 94 eyes with double iStent implant and 7.5 ± 2.2 mmHg in the 98 eyes on medical therapy (beta-blocker and prostaglandin). The WMD was -0.60 (95% CI -1.29, 0.09) in favour to iStent surgery. Considering baseline wash-out IOP values, IOP changes showed greater reduction in both groups: 12.2 ± 2.3 and 11.6 ± 2.2 in iStent and medication group respectively. The WMD did not show any difference, -0.60 (95% CI -1.25, 0.05) in favour to iStent surgery (Fig 2). Change analysis in number of medications could not be performed because all patients were on one anti-glaucomatous drug before randomization. Risk of bias analysis showed unclear risk in four domains and low risk in two domains (S1 Table).

In the RCT by Vold [41] 54 naïve eyes were randomized to double iStent implantation and 47 eyes to medical therapy (prostaglandin). It emerged a greater IOP reduction in the iStent group (11.8 ± 2.65 mmHg) than in the medication group (11.2 ± 4.4 mmHg), WMD = -0.60 (95%CI -2.05, 0.85), Fig 2. Analysis on medication change was not conducted because of per-protocol use of anti-glaucomatous medications. The study was at high risk of bias in one domain (S1 Table).

Meta-analysis was performed on these two studies. Implantation of 2 iStent caused a slightly larger reduction in IOP compared to medical therapy, WMD = -0.60 (95% CI -1.23, 0.03), I-squared = 0.0%, p = 0.060; however this benefit was modest and the 95% CI included no difference.

**MIGS devices versus other glaucoma surgeries.** Four papers (1 RCT, 3 NRS including 30 and 347 patients respectively) compared MIGS with other glaucoma surgeries. In three studies (1 RCT and 2 NRS) MIGS were performed as solo procedures while in one NRS MIGS and its comparator were performed together with cataract surgery.

ELT: one RCT [51] compared ELT surgery with SLT on 30 patients. Medicated IOP data were reported and showed at 1 year a mean change of 9.0 ± 2.4 mmHg and 4.9 ± 1.8 mmHg in the MIGS and control groups respectively. WMD was -4.1 (95% CI -5.62, -2.58) in favor of ELT surgery (Fig 2). The change in the number of glaucoma medication was not reported at one year. At two years after surgery the IOP change in the ELT group was slightly inferior than it was after 12 months (S2 Fig). Glaucoma medication were reported at 2 years, with a WMD of -1.54 (95% CI -2.05, -1.03) in the ELT group compared to baseline values. The study was at low risk of bias in all domains but one which was judged unclear (S1 Table).

HYDRUS: one NRS [48] compared combined Hydrus surgery with SLT on 56 patients. Medicated IOP data were reported and showed at 1 year a mean change of 6.6 ± 5.6 mmHg and 7.3 ± 2.5 mmHg in the MIGS and SLT group respectively. WMD was 0.69 (95% CI -1.55, 2.93) in favor of SLT (Fig 2). The change in the number of glaucoma medication was 1.39 ± 0.97 and 0.48 ± 1.1 in the MIGS and SLT group respectively. WMD was -0.91 (95% CI -1.45, -0.37) in favor of Hydrus surgery (Fig 3). The study was at moderate risk of bias in three domains and at low risk in four domains (S3 Table).

TRABECTOME: one study (NRS) compared Trabectome and cataract surgery with trabecular aspiration and cataract surgery on 55 patients [24]. In the study, medicated IOP data were reported and showed at 1 year a mean change of 9.3 ± 5.6 mmHg and 5.1 ± 6.4 mmHg in the MIGS and control groups respectively. WMD was -4.2 (95% CI -7.38, -1.02) in favor of Trabectome combined surgery (Fig 2). The change in the number of glaucoma medication was 0.29 ± 1.0 and -0.08 ± 1.22 in the MIGS and control group respectively. WMD was -0.37 (95%
CI -0.96, 0.22) in favor of Trabectome surgery (Fig 3). The study was at serious risk of bias in one domain and at moderate and low risk in other domains (S2 Table).

One study (NRS) compared Trabectome surgery with a modified goniotomy technique on 49 PEX and 187 POAG patients [28]. Medicated IOP data on PEX patients were reported and showed at 1 year a mean change of 9.7 ± 9.3 mmHg and 6.7 ± 7.4 mmHg in the MIGS and control groups respectively. WMD was -2.92 (95% CI -7.59, 1.75) in favor of Trabectome surgery. Different results were reported in POAG patients where mean IOP change at 1 year was 4.6 ± 5.4 mmHg and 5.8 ± 7.0 mmHg in the MIGS and control groups respectively. WMD was 1.24 (95% CI -0.69, 3.17) in favor of modified goniotomy surgery (Fig 2). The change in the number of glaucoma medication in the PEX cohort was 0.56 ± 0.94 and 0.67 ± 1.28 in the MIGS and control group respectively. WMD was 0.11 (95% CI -0.53, 0.75) in favor of modified goniotomy surgery. Similar findings were observed in the POAG cohort where the change in the number of glaucoma medication was 0.25 ± 0.9 and 1.1 ± 1.1 in the MIGS and control group respectively. WMD was 0.85 (95% CI 0.54, 1.16) in favor of modified goniotomy surgery (Fig 3). The study was at serious risk of bias in two domains (S2 Table).

MIGS procedures versus other MIGS procedures. 1 ISTENT versus 2 and 3 ISTENT: in the RCT by Katz, 38 subjects were implanted with one stent, 41 subjects with two stents, and 40 subjects with three stents. At 12 months, a greater efficacy of 2 versus 1 iStent implantation has been demonstrated, with mean differences in reduction of 1.90 mmHg (95% CI 1.18–2.62). Higher IOP reduction resulted after 3 iStent implantation, with mean IOP change from baseline of 8.2 mmHg compared to 5.4 mmHg after 1 iStent implantation (only results on 1 and 2 iStent are showed in Fig 2). Considering wash-out IOP, the difference in reduction between 1 and 2 iStent was 1.30 mmHg (95% CI 0.38, 2.22), in favor to 2 iStent. Number of medication decreased of 1.60 drug/patient in the 1iStent group, 1.64 in the 2 iStent group and 1.43 in the 3 iStent group. This study showed a high risk of performance and detection bias because of lack of masking (S1 Table).

TRABECTOME versus ISTENT: three studies compared Trabectome to iStent surgery combined [22, 23, 25]. In these three NRS, 2 iStent were implanted in a total of 108 patients with POAG and cataract, while Trabectome and phacoemulsification were performed in 113 patients. In the NRS by Gonnermann [22], slightly greater IOP reduction was observed in the iStent arm (25 eyes), with IOP change of 7.3 ± 4.1 mmHg, compared to 6.7 ± 4.3 mmHg in the Trabectome arm (25 eyes), WMD = 0.60 (95% CI -1.72, 2.92), Fig 2. Results of number of medication showed greater reduction in the iStent group (0.76 ± 1.06 drug/patient) compared to the Trabectome group (0.64 ± 1.21), but this was not statistically significant (WMD = 0.12, 95% CI -0.51, 0.75), Fig 3. This study was at serious risk of bias in four domains (S2 Table).

Khan [23] reported that iStent group (49 eyes) achieved greater IOP reduction in comparison to the Trabectome group of 52 eyes (5.3 ± 5.3 mmHg vs 3.3 ± 7.9 mmHg respectively) resulting in 2 mmHg of difference (95% CI -0.60, 4.60), Fig 2. Difference in number of medication was in favor to iStent procedure, WMD = 0.89 (CI 0.42, 1.36), Fig 3. This study was at serious risk of bias in three domains (S2 Table).

Kurji [25] reported greater effect in the Trabectome (36 eyes) than in the iStent (34 eyes) arm: IOP change was respectively 5.1 ± 5.9 mmHg and 3.8 ± 3.9 mmHg, WMD = -1.25 (95% CI -3.7, 1.2), Fig 2. Number of medication change was respectively 0.49 ± 1.25 drug/patient and 0.26 ± 0.7 drug/patient, WMD = -0.23 (95% CI -0.72, 0.26), Fig 3. This study was at serious risk of bias in two domains (S2 Table).

The meta-analysis of these three studies on IOP change, with moderate heterogeneity (I-square = 24.3%), showed no difference between Trabectome and iStent as combined procedures, WMD = 0.41 (95% CI -1.40, 2.21), p = 0.65. Meta-analysis on the number of medication was not carried out due to high heterogeneity (I-squared = 73.2%).
Outcomes in before-after studies

**IOP change.** Considering all papers as before-after studies (only MIGS arm in the RCT and NRS), all the MIGS procedures result in a significant reduction of IOP (Fig 4).

The highest reductions was achieved by the study considering naïve patients (WMD = -11.8 in Vold study [41]) followed by studies on Trabectome in PEX subgroups (WMD = -10.60 [26], -9.70 and -9.66 [26, 28]). ELT confirmed the hypotensive efficacy showed in the comparative analysis (WMR = -9 [51] and -8.60 [50] in the RCT and NRS respectively). As regards the iStent, combined procedures showed a lower IOP reduction compared to solo procedure.

The Hydrus combined study [46] showed a WMD of -2.80 mmHg at one year after surgery, lower than that observed in the Hydrus as a solo procedure study (WMD = -6.59) [48].

Two years after surgery, overall IOP reduction was similar to that found at one year: WMD ranged from -1.50 [30] to -11.70 in a wash-out study [43], although a smaller number of studies was considered (S1 Fig).

**Number of glaucoma medications.** Five studies did not report outcomes on the number of glaucoma medications at one year [38,42,47,50,51]. Four studies reported the number of medications used per protocol [37–40] while one study reported none glaucoma medication at last follow-up [35]. Finally, one study was conducted on glaucoma naive patients [41]. Thus, Forest plot of the different in change in glaucoma medication reduction comprised a smaller number of studies (Fig 5).

The XEN [45] as a combined procedure and the iStent [36] as a solo procedure gave the highest reduction in glaucoma medications compared to before surgery values (WMD = -2.90 and WMD = -1.60 drugs/patient respectively).

Two years after surgery, glaucoma medication reduction was apparently higher compared to 1-year: all WMD, except one, were over 1 drug/patient (S2 Fig). However, the number of papers available for 2 year-analysis was low (n = 8 [29,30,33,43,46,47,50,51]) and studies with both one and two-year data did not show glaucoma medication reduction between these timelines [29,30,33,43,46]. Three studies [47,50,51] provided a medication reduction report at two years only.

Adverse outcomes

Postoperative ocular adverse events are summarized in Table 5.

Adverse events were reported in most studies while some others just reported sentences like “no serious adverse event were observed”.

There was no report of postoperative infection or BCVA loss > 2 lines due to glaucoma. The most frequent adverse events were IOP spikes, that occurred in the iStent, in the Cypass and in the Hydrus both as solo (iStent range 1.1% - 10.1% [39,42]; Cypass 10.8% [44]; Hydrus 4.76% and 6.5% [47,48]) and combined procedures (iStent range 0%-21% [31,29]; Cypass 4.3% [43]; Hydrus 4% [46]). In the Trabectome and in the ELT, IOP spikes were respectively reported just for combined (range 5.6%-32.7% [25,23]) or solo procedures (20% [51]).

Additional surgery included trabeculectomy, shunt / valve implant, cyclophotocoagulation, deep sclerectomy or other MIGS procedures.

Discussion

We have performed a systematic review of the studies comparing MIGS techniques, alone or combined with cataract surgery, with medical or laser therapy, cataract surgery or other MIGS techniques.

This paper presents results from studies with three different designs: RCT, NRS and before-after. One-year results of RCT and NRS have been presented together while before-after
| STUDY | DESIGN | WMD (95% CI) | N mean (SD); after | N mean (SD); before |
|-------|--------|--------------|--------------------|---------------------|
| 1 ISTENT COMBINED | Arnola-Villalobos 2012 | BEF/AFT | -2.14 (-3.81, -0.47) | 19.17 (3.21) | 19.19 (4.69) |
| | Craven 2012 | RCT | -1.60 (-2.47, -0.73) | 98.17 (2.8) | 98.18 (3.4) |
| | Fea 2015 | RCT | -3.10 (-4.96, -1.24) | 10.14 (1.3) | 10.17 (2.7) |
| | Spiegel 2009 | BEF/AFT | -4.30 (-5.74, -2.86) | 42.17 (2.98) | 48.21 (3.98) |
| 1 ISTENT SOLO | Katz 2015 | RCT | -5.40 (-9.97, -0.83) | 37.14 (1.2) | 38.18 (1.3) |
| 2 ISTENT COMBINED | Arnola-Villalobos 2016 | BEF/AFT | -3.20 (-5.10, -1.30) | 20.16 (2.24) | 20.19 (3.71) |
| | Khan 2015 | NRS | -5.30 (-7.02, -3.58) | 49.14 (3.1) | 49.16 (5.3) |
| | Donnenfeld 2015 | BEF/AFT | -7.10 (-9.76, -4.46) | 25.14 (2.3) | 25.21 (3.4) |
| | Ahmed 2014 | BEF/AFT | -9.20 (-10.18, -8.22) | 39.13 (2.4) | 39.22 (2.9) |
| | Voskanian 2014 | BEF/AFT | -6.40 (-7.41, -5.39) | 88.15 (3.4) | 99.22 (3.3) |
| | Katz 2015 | RCT | -7.30 (-7.95, -6.65) | 41.12 (1.8) | 41.20 (1.6) |
| | Lindstrom 2016 | BEF/AFT | -5.30 (-5.93, -4.67) | 57.14 (2.19) | 57.19 (1.5) |
| 3 ISTENT SOLO | Katz 2015 | RCT | -8.20 (-8.93, -7.47) | 38.12 (1.5) | 40.20 (1.8) |
| CYPASS COMBINED | Vold 2016 WO | RCT | -7.60 (-8.15, -7.05) | 374.16 (4.67) | 374.24 (2.8) |
| CYPASS SOLO | Garcia-Feijoo 2015 | BEF/AFT | -8.10 (-9.97, -6.49) | 55.16 (5.5) | 65.24 (5.8) |
| ELT COMBINED | Töteberg-Harms 2013 | BEF/AFT | -4.60 (-6.29, -2.91) | 64.15 (4.4) | 64.19 (5.3) |
| ELT SOLO | Babighian 2006 | NRS | -6.80 (-9.84, -3.76) | 21.16 (2.1) | 21.24 (2.8) |
| | Babighian 2010 | RCT | -9.00 (-10.47, -7.53) | 15.16 (2.2) | 15.25 (1.9) |
| HYDRUS COMBINED | Pfeiffer 2015 | RCT | -2.80 (-4.04, -1.56) | 48.16 (1.29) | 50.18 (3.3) |
| HYDRUS SOLO | Fea 2016 | NRS | -6.59 (-8.61, -4.57) | 30.16 (2.6) | 31.23 (5.08) |
| TRABECTOME COMBINED | Klamm 2013 | NRS | -9.30 (-11.68, -6.92) | 27.14 (2.32) | 27.23 (5.86) |
| | Ting 2012 | NRS | -4.30 (-5.06, -3.54) | 247.15 (3.62) | 263.19 (5.9) |
| | Paltlitzsch 2015 PEX | NRS | -10.60 (-13.07, -8.13) | 54.12 (6.1) | 54.23 (9.2) |
| | Gonnemann 2016 | NRS | -6.70 (-8.72, -4.68) | 25.16 (3.6) | 25.22 (3.7) |
| | Kurj 2016 | NRS | -5.09 (-7.19, -2.99) | 33.15 (3.8) | 36.20 (5.07) |
| | Ting 2012 PEX | NRS | -7.50 (-10.13, -4.87) | 42.14 (2.31) | 45.21 (8.4) |
| | Khan 2015 | NRS | -3.30 (-5.86, -0.74) | 52.17 (3.65) | 52.20 (6.8) |
| | Paltlitzsch 2015 | NRS | -7.40 (-8.27, -6.53) | 130.11 (3.1) | 130.19 (2.4) |
| TRABECTOME SOLO | Paltlitzsch 2015 PEX | NRS | -9.70 (-12.82, -6.58) | 40.14 (3.3) | 40.23 (7.9) |
| | Paltlitzsch 2015 | NRS | -5.00 (-6.95, -3.05) | 78.14 (3.2) | 78.19 (5.9) |
| | Paltlitzsch 2016 | NRS | -4.57 (-5.72, -3.42) | 119.13 (3.59) | 119.18 (5.3) |
| | Paltlitzsch 2016 PEX | NRS | -9.68 (-13.48, -5.84) | 27.12 (2.71) | 27.21 (9.77) |
| XEN COMBINED | Pérez-Torregrosa 2016 | BEF/AFT | -6.17 (-7.67, -4.67) | 30.15 (2.47) | 30.21 (3.4) |

Fig 4. Forest plot for 12-months IOP reduction (divided by device and procedure). Values expressed in Weighed Mean Difference (WMD).

https://doi.org/10.1371/journal.pone.0183142.g004
studies have been reported separately with MIGS arms from both RCT and NRS. In general, due to the higher intrinsic value of RCT, it’s difficult to compare their results with those from other study subtypes. However, due to the high number of non RCT papers and the growing

| STUDY               | DESIGN      | WMD (95% CI)      | N_mean (SD); after | N_mean (SD); before |
|---------------------|-------------|-------------------|--------------------|---------------------|
| 1 ISTENT COMBINED   | BEF/AFT     | -1.20 (-1.49, -0.91) | 4.62              | 48.16 (8)           |
| Spiegel 2009        | RCT         | -1.50 (-2.21, -0.79) | 10.47             | 10.19 (9)           |
| Fea 2015            | RCT         | -1.40 (-1.63, -1.20) | 18.68             | 96.16 (8)           |
| Arriola-Villalobos 2012 | BEF/AFT | -1.15 (-1.42, -0.86) | 17.37             | 19.13 (48)          |
| 1 ISTENT SOLO       | RCT         | -1.60 (-1.82, -1.38) | 11.31             | 38.17 (61)          |
| Katz 2015           | BEF/AFT     | -1.00 (-1.38, -0.62) | 3.57              | 20.13 (66)          |
| Arriola-Villalobos 2016 | NRS         | -0.26 (-0.85, 0.33) | 31.19             | 34.25 (121)         |
| Kurji 2016          | NRS         | -1.64 (-2.08, -1.20) | 49.12             | 49.26 (91)          |
| Khan 2015           | NRS         | -1.80 (-2.37, -1.23) | 1.13              | 28.28 (8)           |
| Belovay 2012        | NRS         | -0.76 (-1.34, -0.18) | 25.12             | 25.24 (89)          |
| Gonnermann 2016     | NRS         | (Excluded)         | 17.00             | 17.11 (5)           |
| Fernández-Barrientos 2015 | RCT | -1.64 (-1.85, -1.43) | 12.4              | 41.17 (54)          |
| 2 ISTENT SOLO       | RCT         | -1.43 (-1.66, -1.20) | 8.27              | 40.15 (69)          |
| Katz 2015           | RCT         | -1.20 (-1.31, -1.09) | 2.60              | 37.14 (9)           |
| CYPASS COMBINED     | BEF/AFT     | -0.80 (-1.24, -0.36) | 1.14              | 65.22 (11)          |
| Vold 2016 WO        | RCT         | -0.90 (-1.34, -0.46) | 1.54              | 64.24 (11)          |
| CYPASS SOLO         | BEF/AFT     | -1.50 (-1.92, -1.08) | 5.13              | 50.2 (1)            |
| García-Feijoo 2015  | RCT         | -1.39 (-1.86, -0.92) | 9.04              | 31.22 (83)          |
| ELT COMBINED        | BEF/AFT     | 0.00 (-0.28, 0.28)  | 130.23             | 130.23 (8)          |
| Töteberg-Harms 2013 | RCT         | -0.80 (-1.16, -0.44) | 1.48              | 54.22 (11)          |
| HYDRUS COMBINED     | RCT         | -0.29 (-0.82, 0.24)  | 27.2              | 27.29 (99)          |
| Pfeiffer 2015       | NRS         | -0.64 (-1.31, 0.03)  | 25.14             | 25.2 (12)           |
| HYDRUS SOLO         | NRS         | -0.75 (-1.22, -0.28) | 2.15              | 52.29 (11)          |
| Fea 2016            | NRS         | -0.75 (-0.95, -0.55) | 1.65              | 263.24 (1)          |
| TRABECTOME COMBINED | NRS         | -0.96 (-1.46, -0.46) | 2.15              | 45.23 (99)          |
| Pahlitzsch 2015     | NRS         | -0.49 (-1.11, 0.13)  | 3.76              | 36.25 (134)         |
| Pahlitzsch 2015 PEX | NRS         | -0.25 (-0.48, -0.02) | 19.21             | 119.24 (9)          |
| Klamann 2013        | NRS         | -0.56 (-1.05, -0.07) | 1.19              | 27.25 (103)         |
| Gonnermann 2016     | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| Khan 2015           | NRS         | 0.56 (-0.56, 0.03)  | 24.12             | 40.24 (9)           |
| Ting 2012           | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| Ting 2012 PEX       | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| Kurji 2016          | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| TRABECTOME SOLO     | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| Pahlitzsch 2016 PEX | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| Pahlitzsch 2015     | NRS         | -0.50 (-0.83, -0.17) | 2.12              | 72.26 (8)           |
| XEN COMBINED        | BEF/AFT     | -2.90 (-3.24, -2.56) | 30.17             | 30.37 (69)          |

Fig 5. Forest plot for 12-months number of medication reduction (divided by device and procedure). Values expressed in Weighed Mean Difference (WMD).

https://doi.org/10.1371/journal.pone.0183142.g005
Table 5. Surgery-related adverse events of included studies.

| Device          | Author, Year | Eye (N) | FOLLOW-UP (MONTHS) | IOP SPIKE N (%) | INFECTION N (%) | HYPOTONY N (%) | BCVA LOSS >2 LINES DUE TO GLAUCOMA N (%) | ADDITIONAL DEVICE-RELATED PROCEDURE N (%) | ADDITIONAL SURGERY N (%) |
|-----------------|--------------|---------|--------------------|-----------------|-----------------|---------------|----------------------------------------|------------------------------------------|------------------------|
| TRABECTOME      | GONNERMANN, 2016<sup>22</sup> | 27      | 12                 | NR              | 0               | 0             | 0                                      | NR                        | 2/27 (7.4)             |
|                 | KHAN, 2015<sup>23</sup> | 52      | 12                 | 17/52 (32.7)    | 0               | 0             | NR                                    | 3/52 (5.8)<sup>a</sup> | 4/52 (7.7)             |
|                 | KURJI, 2016<sup>25</sup> | 36      | 12                 | 2/36 (5.6)      | NR              | NR            | NR                                    | NR                        | 3/36 (8.3)             |
|                 | PAHLITZSCH, 2015 (POAG)<sup>30</sup> | 130     | 12                 | *               | *               | *            | *                                      | *                        | *                      |
|                 | PAHLITZSCH, 2015 (PEX)<sup>30</sup> | 54      | 12                 | *               | *               | *            | *                                      | *                        | *                      |
|                 | TING, 2012 (POAG)<sup>27</sup> | 263     | 12                 | 26/263 (9.9)    | 0               | 0             | 0                                      | NR                        | 16/263 (6.1)           |
|                 | TING, 2012 (PEX)<sup>27</sup> | 45      | 12                 | 4/45 (8.9)      | 0               | 1/45 (2.2) | 0                                      | NR                        | 3/45 (6.7)             |
| SOLO            | PAHLITZSCH, 2015 (POAG)<sup>30</sup> | 72      | 12                 | *               | *               | *            | *                                      | *                        | *                      |
|                 | PAHLITZSCH, 2015 (PEX)<sup>30</sup> | 40      | 12                 | *               | *               | *            | *                                      | *                        | *                      |
|                 | PAHLITZSCH, 2016 (POAG)<sup>30</sup> | 119     | 12                 | 0               | 0               | 0            | 0                                      | NR                        | 5/119 (4.2)            |
|                 | PAHLITZSCH, 2016 (PEX)<sup>30</sup> | 27      | 12                 | 0               | 0               | 0            | 0                                      | NR                        | 0                      |
| ISTENT          | ARRIOLA-VILLALOBOS, 2012<sup>29</sup> | 19      | 60                 | 4/19 (21)       | *               | 0            | 0                                      | 0<sup>b</sup>            | 0                      |
|                 | CRAVEN<sup>c</sup>, 2012<sup>30</sup> | 116     | 24                 | 5/116 (4.3)     | 0               | 0            | 0                                      | 5/116 (4.3)             | 1/116 (0.9)            |
|                 | FEA, 2015<sup>31</sup> | 10      | 48                 | 0<sup>b</sup>   | 0<sup>b</sup>   | 0<sup>b</sup> | 0<sup>d</sup> | 0<sup>b</sup> | 0                      |
|                 | SPIEGEL<sup>c</sup>, 2009<sup>32</sup> | 58      | 12                 | 1/58 (1.7)<sup>d</sup> | NR | 0 | 0 | 7/58 (12)<sup>e</sup> | 2/58 (3.5) |
| 2 STENT         | ARRIOLA-VILLALOBOS 2016 (INJECT)<sup>33</sup> | 20      | 12                 | 3/20 (15)       | 0               | 0            | 0                                      | 1/20 (5)                     | 0                      |
|                 | BELOVAY<sup>c</sup>, 2012<sup>24</sup> | 28<sup>f</sup> | 12                 | *               | *               | *            | 0/53                                   | 6/53 (11.3)<sup>f</sup> | *                      |
|                 | GONNERMANN, 2016 (INJECT)<sup>32</sup> | 27      | 12                 | NR              | 0               | 0            | 0                                      | NR                        | 2/27 (7.4)             |

(Continued)
| Device       | Author, Year | Eye (N) | FOLLOW-UP (MONTHS) | IOP SPIKE N (%) | INFECTION N (%) | HYPOTONY N (%) | BCVA LOSS >2 LINES DUE TO GLAUCOMA N(%) | ADDITIONAL DEVICE-RELATED PROCEDURE N(%) | ADDITIONAL SURGERY N(%) |
|--------------|--------------|---------|--------------------|-----------------|-----------------|----------------|------------------------------------------|-----------------------------------------------|------------------------|
| KHAN, 2015   | 23           | 49      | 12                 | 8/49 (16.3)     | 0               | 2/49 (4.1)     | NR                                       | 3/49 (63)                                      | 0                      |
| KURJI, 2016  | 25           | 34      | 12                 | 2/34 (5.9)      | NR              | NR             | NR                                       | NR                                                          | 0                      |
| SOLO         |              |         |                    |                 |                 |                |                                          |                                               |                        |
| 1 STENT      |              |         |                    |                 |                 |                |                                          |                                               |                        |
| KATZ, 2015   | 36           | 38      | 18                 | * * * * *       | * * * *         | *             | 0                                        |                                               |                        |
| 2 STENT      |              |         |                    |                 |                 |                |                                          |                                               |                        |
| AHMED, 2014  | 37           | 39      | 18                 | * *             | 1/39 (2.6)      | 0             | *                                        |                                               |                        |
| DONNENFELD, 2015 | 38          | 39      | 36                 | 1/39 (2.6)      | *               | 0             | 0                                        | 1/39 (2.6)                                      |                        |
| KATZ, 2015   | 36           | 41      | 18                 | * *             | *               | *             | *                                        |                                               |                        |
| FEA, 2014 (INJECT) | 39 | 94   | 12                 | 1/94 (1.1)      | 0              | 0              | 0                                        | 1/94 (1.1)                                      |                        |
| LINDSTROM, 2016 (INJECT) | 40 | 57 | 18                 | *               | *               | *             | *                                        |                                               |                        |
| VOLD, 2016   | 41           | 54      | 36                 | * *             | *               | *             | *                                        |                                               |                        |
| VOSKANYAN, 2014 (INJECT) | 42 | 99   | 12                 | 10/99 (10.1)    | 0               | 0              | 0                                        | 4/99 (4)                                       | 4/99 (4)               |
| 3 STENT      |              |         |                    |                 |                 |                |                                          |                                               |                        |
| CYPASS       |              |         |                    |                 |                 |                |                                          |                                               |                        |
| COMBINED     |              |         |                    |                 |                 |                |                                          |                                               |                        |
| VOLD, 2016   | 43           | 374     | 25                 | 16/374 (4.3)    | 0               | 11/374 (2.9)  | 4/374 (1.1)                              | NR                                            | 3/374 (0.8)           |
| SOLO         |              |         |                    |                 |                 |                |                                          |                                               |                        |
| GARCÍA-FEIJOO, 2015  | 44 | 65 | 12                 | 7/65 (10.8)     | 0               | 0              | 0                                        | 1/65 (1.5)                                    | 12/65 (18.5)          |
| XEN          |              |         |                    |                 |                 |                |                                          |                                               |                        |
| COMBO        |              |         |                    |                 |                 |                |                                          |                                               |                        |
| PEREZ-TORREGROSA, 2016 | 45 | 30 | 12                 | *               | *               | 0             | 0                                        | 7/30 (23.3)                               | *                      |
| HYDRUS       |              |         |                    |                 |                 |                |                                          |                                               |                        |
| COMBO        |              |         |                    |                 |                 |                |                                          |                                               |                        |
| PFEIFFER, 2015 | 46 | 50 | 24                 | 2/50 (4)        | 0               | 0             | 0                                        | NR                                            | 1/50 (2.1)            |
| SOLO         |              |         |                    |                 |                 |                |                                          |                                               |                        |
| GANDOLFI, 2016 | 47 | 21 | 24                 | 1/21 (4.76)     | NR              | NR            | NR                                       | 4/21 (19.05)                                 | 2/21 (9.5)            |
| FEA, 2016    | 48           | 31      | 12                 | 2 (6.5)         | 0              | 0             | 0                                        | 0                                              | 0                      |

(Continued)
| Device | Author, Year | Eye (N) | FOLLOW-UP (MONTHS) | IOP SPIKE N (%) | INFECTION N (%) | HYPOTONY N (%) | BCVA LOSS >2 LINES DUE TO GLAUCOMA N (%) | ADDITIONAL DEVICE-RELATED PROCEDURE N (%) | ADDITIONAL SURGERY N (%) |
|--------|--------------|---------|-------------------|----------------|----------------|----------------|------------------------------------------|-------------------------------------------|------------------------|
| COMBO  | TÔTEBERG-HARMS, 2013<sup>69</sup> | 64      | 12                | NR             | 0              | NR             | NR                                       | NR                                        | 7/64 (10.9)            |
| SOLO   | BABIGHIAN, 2006<sup>70</sup> | 21      | 24                | *              | *              | 0              | *                                        | *                                        | *                      |
|        | BABIGHIAN, 2010<sup>71</sup> | 15      | 24                | 3/15 (20)      | 0              | NR             | NR                                       | NR                                        | NR                     |

SD = standard deviation. POAG = primary open angle glaucoma. Pex = pseudoexfoliative glaucoma. IOP = intraocular pressure. BCVA = best corrected visual acuity. NR = not reported; G1 = iStent. G2 = iStent inject

* = reported in the manuscript as "no serious postoperative complications":

a = 2 goniopuncture, 1 revision

b = reported by corresponding author.

c = safety analysis performed on intent-to-treat population.

d = reported as "corneal paracentesis to reduce IOP".

e = 2 replacement, 1 reposition, 1 argon-laser to remove iris tissue in contact with iStent lumen, 2 TPA, 1 corneal paracentesis.

f = safety reported for 2-stent and 3-stent group together. YAG or argon laser for stent blockage.

g = surgical irrigation of the anterior chamber for hyphema.

h = not specify if related to POAG

i = 19 secondary surgery, not specified.

j = YAG-laser synechiolysis.

https://doi.org/10.1371/journal.pone.0183142.t005
interest on MIGS, it seemed reasonable to include even NRS and before-after. To avoid as much as possible biases deriving from low quality series, we applied strict inclusion-exclusion criteria to NRS and before-after (e.g. patients lost to follow-up > 15%, previous glaucoma surgery). Moreover, meticulous risk of bias assessment has been conducted on all studies, trying to underline their limits and to inform the scientific community about the necessity of well-structured, independent RCTs. The reader should be cautious when interpreting the results we have reported.

Due to the recent introduction of MIGS, we decided to confine our analysis to one-year follow-up data. Nevertheless, two-years analysis of IOP and glaucoma medications, when available, has been provided in the supplementary material. Considering that glaucoma is a chronic disease, two-year data are somehow limited and longer follow-up data is awaited and will certainly be available as soon as MIGS become more widely used. The potential effect of MIGS on subsequent filtering surgery is still to be investigated and any opinion on this matter can only be speculative.

Efficacy analysis

**RCTs.** Only nine RCTs were found [30,31,35,36,39,41,43,46,51], three with small sample sizes (< 100 patients) [31,35,51] on four different MIGS devices (i.e. iStent, Cypass, Hydrus and ELT).

Five RCTs [30,31,35,43,46] compared MIGS and cataract surgery to cataract surgery alone, and one study with a small sample size compared ELT with SLT [51], with the MIGS showing higher IOP and glaucoma medication reduction.

The design of the studies comparing iStent with medical therapy [39,41] was different: in one study patients with uncontrolled glaucoma on one medication were randomized to either a combined drug (beta-blocker and prostaglandin) or to the implant of two iStents [39]; the other study was done in naïve patients randomized to either two iStent or to a prostaglandin [41]. The implantation of the two iStents obtained a larger reduction of IOP than the comparator group in both studies. Of particular interest is the study on naïve patients in which the comparator (one prostaglandin) presented a mean reduction in IOP of 11.2 mm Hg corresponding to a 44.6% IOP reduction, somehow more than the 25–35% generally reported in the literature [54].

One study compared the efficacy of one vs multiple (two or three) iStents implanted in patients with uncontrolled IOP on two pre-operative medications [36]. Multiple iStents seem to provide a significant advantage over a single iStent implant.

To avoid the confounding effect of considering at the same time the IOP reduction and the reduction of medical therapy in three studies comparing cataract surgery with combo surgery (MIGS and cataract), the patients were washed-out both at baseline and after surgery [31,43,46]. The iStent [31] and the Cypass [43] studies demonstrated a significant advantage of the combined surgery over cataract alone, while the Hydrus study [46] demonstrated a modest difference compared to cataract surgery alone. This interpretation of the results is somehow misleading if the absolute IOP change of the MIGS group and the comparator are not taken into account. The absolute IOP reduction in the washed-out patients was higher in the Hydrus study (9.7±4.45 mm Hg) compared to the Cypass (7.9±4.1 mm Hg) and the iStent (1.7± 2.84 mmHg) studies. In the Hydrus study the difference with the comparator was relatively low due to a greater IOP reduction observed in the comparator group (cataract: 9.2±4.69 mm Hg).

Some of the potential inconsistencies regarding the efficacy of the MIGS procedures when compared to cataract surgery can thus be due to the variability of IOP reduction in the cataract surgery group reported in the different studies. The reduction of IOP following cataract
surgery reported elsewhere in the literature is of approximately 5 mmHg [55]. Some of the differences in the IOP reduction after cataract surgery in these studies may be related to the higher baseline IOP as IOP reduction after cataract surgery has been demonstrated to be proportional to the pre-operative IOP.

The IOP lowering effect of MIGS was greater than that of comparators in all studies, although statistical significant difference was borderline or not achieved when meta-analysis was performed. Higher differences were observed in the small ELT vs SLT study by Babighian (4.1 mmHg) [51] and iStent and cataract surgery vs cataract surgery alone by Fea (3.4 mmHg, after 12 months washout) [31] and Fernández-Barrientos (2.8 mmHg) [35]. In RCTs with bigger samples the differences between MIGS and their comparators were smaller, between 0.2 [46] and 1.7 mmHg [43]. However, these data should be evaluated considering the coexisting reduction in glaucoma medication, which was 1.2 [46] and 1.64 [43], thus potentially enlarging the absolute gap between the MIGS and the control arm.

Unfortunately, estimates on the additive IOP lowering effect of medication are impossible to perform, due to the different effect on IOP of different molecules and to the inter-subject variability of response to the medications. Baseline and postoperative wash-out IOP values are therefore highly recommended.

As a matter of fact it is somehow difficult to provide a systematic comparison between the different MIGS devices mainly because of the small number of studies reporting both the pre and post-operative wash-out pressures, but also because of differences in protocols and inclusion criteria.

**NRS.** Several NRS studies were included in our systematic review: one compared ELT to medical therapy [50], one Hydrus to SLT [48], three iStent to Trabectome [22,23,25], one Trabectome to trabecular aspiration [24] and one Trabectome to a modified goniotomy technique [28]. In the ELT, the Hydrus and the Trabectome vs goniotomy studies, the MIGS procedure were not combined with cataract surgery.

ELT proved to be superior to medical therapy and the Trabectome to trabecular aspiration both in terms of IOP and medication reduction, whereas the study comparing Hydrus to SLT demonstrated a similar IOP reduction but a significant advantage in the number of medications after the implantation of the Hydrus device.

A non significant advantage of the Trabectome over a modified goniotomy technique was demonstrated in PEX patients only [28]. The comparison of the Trabectome vs 2 iStent proved either in favour of one method or the other [22,25] but the difference was significant in one study only, showing a greater reduction of IOP and medications in the iStent group [23].

Our meta-analysis did show an acceptable heterogeneity for the iStent studies (iStent combined vs phacoemulsification; iStent solo vs medical therapy and iStent vs Trabectome combined), whereas were poor in the Trabectome vs modified goniotomy study. There were no significant differences between the results obtained in the different groups.

**Before-after studies.** Because of the limited research available on the effect of MIGS, we also reported on the IOP lowering effect in before/after studies and in the MIGS arm of RCTs and NRSs, consistently showing an IOP reduction from 1.60 [30] to 11.8 mmHg [41] and a medication reduction by 0 [26] to 2.9 [45]. Although such information should be interpreted with caution, since the starting IOP control and measurement setting was not well reported, these series suggest a potential for IOP lowering by most MIGS and encourage the conduction of further comparative research using good-quality methods and comparators that are meaningful alternatives in modern glaucoma practice.

**Solo versus combined studies.** Several studies investigated the efficacy of the MIGS (Trabectome [26–28], iStent [36–42], ELT [50,51], Hydrus [47,48], Cypass [44]) as a solo procedure. All the studies were favorable to MIGS both in term of IOP reduction (-4.57 to -11.80)…
and medications reduction (-0.10 to -1.64) [26,36], thus suggesting that the MIGS can be effective independently from cataract surgery.

The observation that several solo procedures (iStent, Hydrus and ELT) outperformed combined surgery is somehow unexpected because the reduction of IOP achieved by phacoemulsification alone should add to the effect of the glaucoma procedures [56–58]. This difference is particularly evident when considering the iStent because of the larger number of studies and could not be attributed to either the implantation of different iStent models not to the implantation of multiple devices. Most of the solo iStent studies were performed later and a possible explanation of their apparent better performance could lie in improved surgical techniques and more appropriate selection criteria. Some of the later iStent studies have been performed in areas where the access to pharmacological treatment may be difficult and those patients may have been less exposed to potential negative effect of prolonged topical therapy.

Although the potential negative effect of the prolonged use of glaucoma medications on the results of MIGS device has never been hypothesized, this has been demonstrated with other laser [59] and surgical procedures [60].

Safety

The number of complications is missing in some of the studies [26,41], but it is minimal whenever reported. In particular there were no reports of infection or decrease in Best Corrected Visual Acuity (BCVA). IOP spikes incidence ranged from 0 to 32.7% [28,31 and 23]. Revision of the procedure was relatively low for the iStent (0 to 6.89%) [29,31 and 32] and more common following the XEN implantation (23.3%) [45], which relies on the presence of a conjunctival bleb. Additional surgery was done in less than 10% of patients with the exception of the Cypass (18.5%) [44] and the ELT (10.9%) [49].

Risk of bias

Considering the RCT studies, some methodological issues deserve discussion. In most of the studies a clear definition of the randomization method is lacking. The masking of most RCT has been judged as unclear, but it should be pointed out that masking a surgical procedure can be almost impossible both to the patient and to the examiner due to the fact that the device can sometimes be clearly visible. IOP should ideally be recorded by a masked technician or with a two-person system.

Because of the limited amount of evidence, we expanded our analysis by presenting uncontrolled before/after series as well as data from the MIGS arm of NRS and RCTs to yield a better picture of the knowledge in this field.

We adopted ROBINS-I [16], a recently developed methodological tool, to assess the risk of bias in NRS as well as in uncontrolled before/after studies. However, we caution readers regarding the fact that the use of ROBINS-I to assess before/after series is not validated and should be considered experimental unless a specific version is made available by the developers.

When assessing the methodological quality of non-randomized studies, we paid particular attention to specific issues, which apply to both NRS and uncontrolled before/after studies. First, IOP measurement should have been carefully collected, ideally by personnel unaware of the treatment status and not by the treating physician; a minimum of three IOP measurement or a diurnal curve at the before and after point would be useful to limit random error or regression to the mean. Furthermore, in the studies it should be clearly stated if the patients were consecutive, how many patients were excluded during the study and what was the reason for exclusion and how many patients were lost to follow-up.
To minimize the reciprocal effect of IOP reduction and medical therapy reduction, wash-out is advisable and if not deemed possible a staged re-introduction of medical therapy would be advisable. Following predefined rules, it would be clear, then, that a single therapy would correspond to a certain compound and that the addition of a second medication would correspond to another definite compound.

Unfortunately, in most NRS and before/after studies the Authors failed to provide details suggesting that such high standards were met. Conflict of interest is believed to be a potential source of bias in clinical studies, including RCTs. It should be noted that several studies are sponsored and this applies to both RCT, NRS and before-after studies. Detailed funding by device industry or authors affiliations are reported (S4 Table). In general, larger studies need some kind of sponsorship as it happens to all multicentric drug studies. Considering the independent studies, it should be noted that some may have benefitted from the free use of the device, which again is common in the pharmaceutical trials, where the cost of the drug is nevertheless incomparable to the price of this kind of devices.

Conclusions

A strength of our review was the inclusion of all available evidence on MIGS techniques, comprising RCTs and NRS and assessing their methodological quality.

Our systematic review has found that, although there is increasing interest on safer, standardized and minimally invasive surgeries, the evidence on the efficacy of MIGS compared to other therapies is still limited and is based on few RCTs of acceptable quality and a larger number of NRS and uncontrolled before/after series.

We suggest that future research should be comparative, ideally randomized, including patients and alternative treatments that are relevant to clinical settings.

The results of this meta-analysis show a decrease of IOP and a reduction of glaucoma medications after MIGS surgery with a low complication rate. This could be potentially very relevant for patients and health care providers, allowing a significant number of POAG patients to reduce their glaucoma medication burden. The remarkable heterogeneity of the studies on this topic suggests the need for additional research to understand how to maximize the utility of these new procedures. The potential influence of prolonged glaucoma medication treatment, as well as the effects of higher pre-operative IOP, patient selection and surgical performances should be examined in future investigations.

Similarly, the impact of these mini-invasive procedures on the reported quality of life of patients and their costs, potentially influencing their diffusion, should be investigated.

Supporting information

S1 Appendix. Search strategy for Medline.
(DOCX)

S2 Appendix. References of studies excluded on the basis of full text.
(DOCX)

S1 Table. Risk of bias summary for RCTs: Review authors’ judgements about each risk of bias item for each included study.
(DOCX)

S2 Table. Risk of bias summary for non-RCTs NRS: Review authors’ judgements about each risk of bias item for each included study.
(DOCX)
S3 Table. Risk of bias summary for non-RCTs Before-after studies: Review authors’ judgements about each risk of bias item for each included study.

S4 Table. Risk of bias sponsor-related for all studies.

S1 Fig. Risk of bias summary for RCTs: Review authors’ judgements about each risk of bias item for each included study.

S2 Fig. Methodological quality graph for RCTs: Review authors’ judgements about each methodological quality item presented as percentages across all included RCTs.

S3 Fig. Methodological quality graph for non-RCTs (NRS): Review authors’ judgements about each methodological quality item of ROBINS-I presented as percentages across all included RCTs.

S4 Fig. Methodological quality graph for non-RCTs (Before-after study): Review authors’ judgements about each methodological quality item of ROBINS-I presented as percentages across all included RCTs.

S5 Fig. Forest plot for 24-months IOP reduction. Values expressed in Weighed Mean Difference (WMD).

S6 Fig. Forest plot for 24-months glaucoma medication reduction. Values expressed in Weighed Mean Difference (WMD).

S7 Fig. PRISMA checklist.

Acknowledgments
We thank Giovannino Ciccone for providing methodological perspective and Chiara Monagheddu for designing the search strategy.
All authors have no known conflicts of interest.

Author Contributions
Conceptualization: Antonio Maria Fea.
Data curation: Carlo Lavia, Laura Dallorto, Milena Maule, Manuela Ceccarelli.
Formal analysis: Carlo Lavia, Laura Dallorto, Milena Maule.
Methodology: Carlo Lavia, Laura Dallorto, Milena Maule, Manuela Ceccarelli.
Resources: Manuela Ceccarelli.
Supervision: Milena Maule, Manuela Ceccarelli, Antonio Maria Fea.
Validation: Milena Maule.
Writing – original draft: Carlo Lavia, Laura Dallorto, Antonio Maria Fea.

Writing – review & editing: Carlo Lavia, Laura Dallorto, Antonio Maria Fea.

References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262–267. https://doi.org/10.1136/bjo.2005.081224 PMID: 16488940

2. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition. Savona, Italy. Editrice PubliComm, 2014.

3. Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K et al. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Surv Ophthalmol. 2015; 122(7):1308–1316.

4. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008; 53 Suppl 1:S57–68.

5. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther. 2000; 22(2):167–208. https://doi.org/10.1016/S0149-2918(00)88478-7 PMID: 10743979

6. Dreer LE, Girkin C, Mansberger SL. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma. 2012; 21(4):234–240. https://doi.org/10.1097/IJG.0b013e31821dac86 PMID: 21623223

7. Gedde SJ, Singh K, Schiffman JC, Feuer WJ. Tube Versus Trabeculectomy Study Group. The Tube Versus Trabeculectomy Study: interpretation of results and application to clinical practice. Curr Opin Ophthalmol. 2012; 23(2):118–126. https://doi.org/10.1097/ICO.0b013e32834f2d1 PMID: 22249235

8. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (T VT) Study after five years of follow-up. Am J Ophthalmol. 2012; 153(5):789–803. https://doi.org/10.1016/j.ajo.2011.10.026 PMID: 22245458

9. Francis BA, Singh K, Lin SC, Hodapp E, Jampel HD, Samples JR et al. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. Ophthalmology. 2011; 118(7):1466–1480. https://doi.org/10.1016/j.ophtha.2011.03.028 PMID: 21724045

10. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012; 23(2):96–104. https://doi.org/10.1097/ICO.0b013e32834f1e7 PMID: 22249233

11. Caprioli J, Kim JH, Friedman DS, Kiang T, Moster MR, Parrish RK 2nd et al. Special Commentary: Supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery: Summary of a Joint Meeting of the American Glaucoma Society and the Food and Drug Administration, Washington, DC, February 26, 2014. Ophthalmology. 2015; 122(9):1795–1801. https://doi.org/10.1016/j.ophtha.2015.02.029 PMID: 25881513

12. Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016; 10:189–206. https://doi.org/10.2147/OPHTHS.80490 PMID: 26869735

13. Brandão LM, Grieshaber MC. Update on Minimally Invasive Glaucoma Surgery (MIGS) and New Implants. J Ophthalmol. 2013;2013:705915. https://doi.org/10.1155/2013/705915 PMID: 24369494

14. Manasses DT, Au L. The New Era of Glaucoma Micro-stent Surgery. Ophthalmol Ther. 2016; 5(2):135–146. https://doi.org/10.1007/s40123-016-0054-6 PMID: 27314234

15. Higgins JPT, Altman DG (editors). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.

16. Sterne JA, Hernan MA, Reeves BC, Savovíc J, Berkman ND, Viswanathan M et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. https://doi.org/10.1136/bmj.i4919 PMID: 27733354

17. Friedrich JO, Adhikari NK, Beyene J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol. 2008; 8:32. https://doi.org/10.1186/1471-2288-8-32 PMID: 18492289

18. Higgins JP, White IR and Anzueto-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat Med 2008; 27:6072–6092. https://doi.org/10.1002/sim.3427 PMID: 18800342

19. Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol. 2016; 70:129–135. https://doi.org/10.1016/j.jclinepi.2015.09.005 PMID: 26386323
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629–634. PMID: 9310563
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Bio- metrics 1994; 50(4):1088–1101. PMID: 7786990
22. Gonnermann J, Bertelmann E, Pahlitzsch M, Maier AK, Torun N, Klamann MK. Contralateral eye com- parison study in MICS & MIGS: Trabectome® vs. iStent inject®. Graefes Arch Clin Exp Ophthalmol. 2017; 255(2):359–365. https://doi.org/10.1007/s00417-016-3514-8 PMID: 27815624
23. Khan M, Saheb H, Neelakantan A, Fellman R, Vest Z, Harasymowycz P, et al. Efficacy and safety of combined cataract surgery with 2 trabecular microbypass stents versus ab interno trabeculectomy. J Cataract Refract Surg. 2015; 41(8):1716–1724. https://doi.org/10.1016/j.jcrs.2014.12.061 PMID: 26432130
24. Klamann MK, Gonnermann J, Maier AK, Ruokonen PC, Torun N, Joussen AM, et al. Combined clear cornea phacoemulsification in the treatment of pseudoxfoliative glaucoma associated with cataract: significance of trabecular aspiration and ab interno trabeculectomy. Graefes Arch Clin Exp Ophthalmol. 2013; 251(9):2195–2199. https://doi.org/10.1007/s00417-013-2408-2 PMID: 23812010
25. Kuri K, Rudinsky CJ, Rayat JS, Arora S, Sandhu S, Damji KF, et al. Phaco-trabeculectomy versus phaco- iStent in patients with open-angle glaucoma. Can J Ophthalmol. 2017; 52(1):99–106. https://doi.org/10.1016/j.jcjo.2016.06.018 PMID: 28237158
26. Pahlitzsch M, Gonnermann J, Maier AK, Torun N, Bertelmann E, Joussen AM, et al. Trabeculectomy Ab Interno in Primary Open Angle Glaucoma and Exfoliative Glaucoma. Klin Monbl Augenheilkd. 2015; 232(10):1198–1207. https://doi.org/10.1055/s-0041-105941 PMID: 26512851
27. Ting JL, Damji KF, Stiles MC. Trabeculectomy Study Group. Ab interno trabeculectomy: outcomes in exfoli- ation versus primary open-angle glaucoma. J Cataract Refract Surg. 2012; 38(2):315–323. https://doi. org/10.1016/j.jcrs.2011.08.043 PMID: 22322166
28. Pahlitzsch M, Gonnermann J, Maier AK, Bertelmann E, Klamann MK, Erb C. Modified goniotomy as an alternative to trabeculectomy in primary open angle glaucoma and pseudoxfoliation glaucoma: 1 year results. Can J Ophthalmol. 2017; 52(1):92–98. https://doi.org/10.1016/j.jcjo.2016.07.011 PMID: 28237157
29. Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, Fernández-Pérez C, García-Sánchez J, García-Feijóo J. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012; 96(5):645–649. https://doi.org/10.1136/bjophthalmol-2011-300218 PMID: 22275344
30. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. iStent Study Group. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012; 38(8):1339–1345. https://doi.org/10.1016/j.jcrs.2012.03.025 PMID: 22814041
31. Fea AM, Consolandi G, Zola M, Pignata G, Cannizzo P, Lavia C, et al. Micro-Bypass Implantation for Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up. J Ophthalmol. 2015; 2015:795357. https://doi.org/10.1155/2015/795357 PMID: 26587282
32. Spiegel D, Wetzel W, Neuhan T, Steuerer J, Hoeh H, Garcia-Feijoo J, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cata- ract surgery. Eur J Ophthalmol. 2009; 19(3):393–399. PMID: 19396784
33. Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, Morales-Fernandez L, Fernandez-Perez C, Garcia-Feijoo J. Glaukos iStent inject® Trabecular Micro-Bypass Implantation Associated with Cataract Surgery in Patients with Coexisting Cataract and Open-Angle Glaucoma or Ocular Hypertension: A Long-Term Study. J Ophthalmol. 2016; 2016:1056573. https://doi.org/10.1155/2016/1056573 PMID: 27882243
34. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012; 38(11):1911–1917. https://doi.org/10.1016/j.jcrs.2012.07.017 PMID: 22980724
35. Fernández-Barrientos Y, García-Feijóo J, Martínez-de-la-Casa JM, Pablo LE, Fernández-Pérez C, García Sánchez J. Fluorophotometric study of the effect of the glaukos trabecular microbypass stent on aqueous humor dynamics. Invest Ophthalmol Vis Sci. 2010; 51(7):3327–3332. https://doi.org/10.1167/iovs.09-3972 PMID: 20207977
36. Katz LJ, Erb C, Carceller GA, Fea AM, Voskanyan L, Wells JM, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clin Ophthalmol. 2015; 9:2313–2320. https://doi.org/10.2147/OPTH.S96695 PMID: 26715834
37. Ahmed II, Katz LJ, Chang DF, Donnenfeld ED, Solomon KD, Voskanyan L, et al. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle
38. Donnenfeld ED, Solomon KD, Voskanyan L, Chang DF, Samuelson TW, Ahmed II, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clin Ophthalmol. 2015; 9:2057–2065. https://doi.org/10.2147/OPTH.S91732 PMID: 26604675

39. Fea AM, Belda JI, Rekas M, Jüinemann A, Chang L, Pablo L, et al. Prospective unmasked randomized evaluation of the iStent inject® versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol. 2014; 8:875–882. https://doi.org/10.2147/OPTH.S9932 PMID: 24855336

40. Lindstrom R, Lewis R, Hombeak DM, Voskanyan L, Giamporcaro JE, Hovanesian J, et al. Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. Adv Ther. 2016; 33(11):2082–2090. https://doi.org/10.1007/s12325-016-0420-8 PMID: 27739003

41. Vold SD, Voskanyan L, Tetz M, Auffarth G, Masood I, Au L, et al. Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months. Ophthalmol Ther. 2016; 5(2):161–172. https://doi.org/10.1007/s40123-016-0065-3 PMID: 27619225

42. Voskanyan L, García-Feijoo J, Belda JI, Fea A, Jüinemann A, Baudouin C. Synergy Study Group. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. Adv Ther. 2014; 31(2):189–201. https://doi.org/10.1007/s12325-014-0095-y PMID: 24452726

43. Vold S, Ahmed II, Craven ER, Mattcox C, Stamper R, Packer M, et al. Two-Year COMPASS Trial Results: Supraciliary Microstenting with Phacoemulsification in Patients with Open-Angle Glaucoma and Cataracts. Ophthalmology. 2016; 123(10):2103–2112. https://doi.org/10.1016/j.ophtha.2016.06.032 PMID: 27506466

44. Garcia-Feijoo J, Rau M, Grisanti S, Grisanti S, Höh H, Erb C, et al. Supraciliary Micro-stent Implantation for Open-Angle Glaucoma Failing Topical Therapy: 1-Year Results of a Multicenter Study. Am J Ophthalmol. 2015; 159(6):1075–1081. https://doi.org/10.1016/j.ajo.2015.02.018 PMID: 25747677

45. Pérez-Torregrosa VT, Olarte-Pérez Á, Cerdá-Ibáñez M, Gargallo-Benedicto A, Osorio-Alayo V, Barreiro-Rego A, et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016; 91(9):415–21. https://doi.org/10.1016/j.oftal.2016.02.006 PMID: 26995503

46. Pfeiffer N, García-Feijoo J, Martinez-de-la-Casa JM, Larrosa JM, Fea A, Lemij H, et al. A Randomized Trial of a Schlemm’s Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma. Ophthalmology. 2015; 122(7):1283–1293. https://doi.org/10.1016/j.ophtha.2015.03.031 PMID: 25972254

47. Gandolfi SA, Ungaro N, Ghirardini S, Tardini MG, Mora P. Comparison of Surgical Outcomes between Canaloplasty and Schlemm’s Canal Scaffold at 24 Months’ Follow-Up. J Ophthalmol. 2016; 2016:3410469. https://doi.org/10.1155/2016/3410469 PMID: 26989497

48. Fea AM, Ahmed II, Lavia C, Mittica P, Consolandi G, Motelese I, et al. Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results. Clin Exp Ophthalmol. 2017; 45(2):120–127. https://doi.org/10.1111/ceo.12805 PMID: 27449488

49. Töteberg-Harms M, Hanso JV, Funk J. Cataract surgery combined with excimer laser trabeculotomy to lower intraocular pressure: effectiveness dependent on preoperative IOP. BMC Ophthalmol. 2013; 13:24. https://doi.org/10.1186/1471-2415-13-24 PMID: 23799332

50. Babighian S, Rapizzi E, Galan A. Efficacy and safety of ab interno excimer laser trabeculotomy in primary open-angle glaucoma: two years of follow-up. Ophthalmologica. 2006; 220(5):285–290. https://doi.org/10.1159/00004616 PMID: 16954703

51. Babighian S, Caretti L, Tavolato M, Cian R, Galan A. Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye (Lond). 2010; 24(4):632–638.

52. Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE. US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology, 2011; 118(3):459–467. https://doi.org/10.1016/j.ophtha.2010.07.007 PMID: 20828829

53. Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, García-Vidal SE, Fernández-Pérez C, García-Sánchez J, et al. Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract. Br J Ophthalmol. 2013 Oct; 97(10):1250–5 https://doi.org/10.1136/bjophthalmol-2012-302394 PMID: 23603758
54. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688–703. PMID: 12719078

55. Poley BJ, Lindstrom RL, Samuelson TW, Schulze R Jr. Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes: evaluation of a causal relationship between the natural lens and open-angle glaucoma. J Cataract Refract Surg. 2009; 35(11):1946–55. https://doi.org/10.1016/j.jcrs.2009.05.061 PMID: 19878828

56. Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol. 2010; 21(2):118–122. https://doi.org/10.1097/ICU.0b013e3283360ac3 PMID: 20040874

57. Melancia D, Abegão Pinto L, Marques-Neves C. Cataract surgery and intraocular pressure. Ophthalmic Res. 2015; 53(3):141–148. https://doi.org/10.1159/000377635 PMID: 25765255

58. Fogagnolo P, Centoftanti M, Figus M, Frezzotti P, Fea A, Ligorio P, et al. Short-term changes in intraocular pressure after phacoemulsification in glaucoma patients. Ophthalmologica. 2012; 228(3):154–158. https://doi.org/10.1159/000337838 PMID: 22572718

59. Fea A.M., Dorin G. Laser treatment of glaucoma: Evolution of laser trabeculoplasty techniques. 2008; 6 (2):45–52

60. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29(4):312–334. https://doi.org/10.1016/j.preteyeres.2010.03.001 PMID: 20302969